MeSH term
Frequency | Condition_Probility | Female | 494 | 0.0 |
Humans | 1661 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 12 | 0.0 |
Randomized Controlled Trials | 6 | 1.0 |
Animals | 367 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Albumins/metabolism | 3 | 2.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Aged | 159 | 0.0 |
Risk | 4 | 0.0 |
Time Factors | 84 | 0.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 2 | 2.0 |
DNA Adducts | 2 | 2.0 |
DNA Damage | 2 | 0.0 |
Drug Resistance, Neoplasm | 3 | 0.0 |
Gene Expression | 30 | 0.0 |
Cooperative Behavior | 2 | 15.0 |
Curriculum | 2 | 28.0 |
History, 20th Century | 4 | 2.0 |
Terminology | 2 | 1.0 |
United States | 7 | 0.0 |
Biological Markers | 11 | 0.0 |
Bladder Neoplasms/genetics/*metabolism | 2 | 5.0 |
Cell Adhesion Molecules/genetics/metabolism | 2 | 4.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
Genes, cdc | 2 | 4.0 |
Oncogenes | 2 | 0.0 |
Telomerase/genetics/metabolism | 2 | 6.0 |
Research Support, Non-U.S. Gov't | 819 | 0.0 |
Forecasting | 5 | 1.0 |
Computer Simulation | 5 | 1.0 |
Cytochrome P-450 Enzyme System/*chemistry/metabolism | 5 | 41.0 |
Escherichia coli/enzymology/genetics | 2 | 3.0 |
Kinetics | 227 | 2.0 |
Ligands | 16 | 0.0 |
Models, Chemical | 15 | 4.0 |
Protein Binding | 48 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 9 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 337 | 0.0 |
Substrate Specificity | 108 | 4.0 |
*Thermodynamics | 2 | 12.0 |
Base Sequence | 65 | 0.0 |
Binding Sites/genetics | 5 | 0.0 |
Cell Line | 83 | 0.0 |
DNA/genetics | 8 | 0.0 |
Gene Expression Regulation | 5 | 0.0 |
Mice | 77 | 0.0 |
Promoter Regions (Genetics) | 14 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Sequence Deletion | 6 | 0.0 |
Adolescent | 90 | 0.0 |
Adult | 418 | 0.0 |
Child | 55 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 77 | 18.0 |
Gene Frequency | 16 | 0.0 |
Haplotypes | 7 | 0.0 |
Male | 641 | 0.0 |
Middle Aged | 293 | 0.0 |
Mutagens/metabolism | 2 | 7.0 |
*Polymorphism, Genetic | 25 | 0.0 |
Risk Factors | 27 | 0.0 |
Variation (Genetics) | 16 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 7 | 38.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 12 | 24.0 |
In Vitro | 201 | 3.0 |
Liver/drug effects/metabolism | 6 | 8.0 |
Mice, Inbred C57BL | 10 | 0.0 |
Mice, Knockout | 9 | 0.0 |
Molecular Sequence Data | 64 | 0.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 9 | 50.0 |
Cytochrome P-450 Enzyme System/metabolism | 109 | 45.0 |
Cytosol/enzymology/metabolism | 2 | 16.0 |
Hydroxylation | 114 | 32.0 |
Liver/cytology/*enzymology | 4 | 21.0 |
Microsomes, Liver/enzymology/*metabolism | 38 | 49.0 |
Recombinant Proteins/metabolism | 103 | 4.0 |
Biological Availability | 47 | 17.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 62 | 52.0 |
Enzyme Inhibitors/isolation & purification/pharmacology | 2 | 28.0 |
Inhibitory Concentration 50 | 23 | 8.0 |
Molecular Structure | 23 | 3.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Stereoisomerism | 53 | 13.0 |
Structure-Activity Relationship | 32 | 1.0 |
Antibodies/pharmacology | 9 | 2.0 |
Antineoplastic Agents, Alkylating/*metabolism | 4 | 57.0 |
*Aryl Hydrocarbon Hydroxylases | 220 | 26.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 71 | 54.0 |
Enzyme Inhibitors/pharmacology | 138 | 5.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 30 | 42.0 |
Microsomes, Liver/drug effects/*enzymology | 22 | 51.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 38 | 82.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/*metabolism | 6 | 33.0 |
Transfection | 70 | 0.0 |
Acute Disease | 6 | 0.0 |
Cytochrome P-450 CYP1A2/*metabolism | 9 | 11.0 |
Cytochrome P-450 CYP2D6/*metabolism | 17 | 48.0 |
Drug Therapy, Combination | 28 | 1.0 |
Treatment Outcome | 17 | 0.0 |
Area Under Curve | 130 | 27.0 |
Clinical Trials | 19 | 2.0 |
Drug Interactions | 299 | 24.0 |
HIV Infections/*drug therapy | 8 | 3.0 |
Microsomes, Liver/metabolism | 56 | 32.0 |
Biotransformation | 122 | 22.0 |
Chromatography, Thin Layer | 3 | 1.0 |
Cytochrome P-450 Enzyme System/*metabolism | 265 | 53.0 |
Imines/*metabolism | 2 | 66.0 |
Insecticides/*metabolism | 5 | 62.0 |
Isoenzymes/metabolism | 67 | 12.0 |
Oxidation-Reduction | 116 | 8.0 |
Solvents | 6 | 11.0 |
Spectrophotometry, Ultraviolet | 22 | 12.0 |
Cytochrome P-450 CYP1A2/*genetics | 3 | 7.0 |
Cytochrome P-450 CYP2D6/*genetics | 3 | 5.0 |
Genotype | 62 | 0.0 |
Mixed Function Oxygenases/*genetics | 30 | 21.0 |
Pharmacogenetics | 9 | 8.0 |
Phenotype | 45 | 0.0 |
Polymorphism, Genetic/*genetics | 13 | 1.0 |
Carcinogens/pharmacokinetics | 2 | 13.0 |
Cytochrome P-450 CYP2E1/metabolism | 15 | 34.0 |
Microsomes, Liver/*enzymology | 82 | 42.0 |
Mixed Function Oxygenases/metabolism | 85 | 60.0 |
Recombinant Proteins | 8 | 1.0 |
Trihalomethanes/*pharmacokinetics | 2 | 100.0 |
Comparative Study | 246 | 0.0 |
Cytochrome P-450 CYP1A2/metabolism | 35 | 35.0 |
Cytochrome P-450 CYP2B1/metabolism | 3 | 27.0 |
Rats | 155 | 1.0 |
Antibiotics, Antitubercular/pharmacology | 4 | 44.0 |
Antifungal Agents/pharmacology | 15 | 39.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
Genes, Reporter | 14 | 0.0 |
Ketoconazole/pharmacology | 59 | 63.0 |
Luciferases/metabolism | 3 | 0.0 |
Models, Genetic | 2 | 0.0 |
Plasmids/metabolism | 4 | 0.0 |
Rifampin/pharmacology | 37 | 59.0 |
Trans-Activation (Genetics) | 9 | 0.0 |
Transcription, Genetic | 17 | 0.0 |
Xenobiotics/*pharmacology | 13 | 44.0 |
Cells, Cultured | 114 | 0.0 |
Coumarins/pharmacology | 4 | 21.0 |
Enzymes/*metabolism | 2 | 13.0 |
Mephenytoin/pharmacology | 3 | 60.0 |
Microsomes, Liver/drug effects/*metabolism | 16 | 40.0 |
Models, Biological | 29 | 0.0 |
Quinidine/pharmacology | 23 | 53.0 |
Sulfaphenazole/pharmacology | 13 | 44.0 |
Theophylline/*analogs & derivatives/pharmacology | 4 | 36.0 |
Alleles | 30 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 63 | 42.0 |
Hepatocytes/enzymology/*metabolism | 4 | 66.0 |
Intestine, Small/enzymology/*metabolism | 2 | 40.0 |
Midazolam/metabolism/*pharmacokinetics | 2 | 100.0 |
Mixed Function Oxygenases/genetics/*metabolism | 22 | 44.0 |
RNA, Messenger/metabolism | 22 | 0.0 |
Sequence Homology, Nucleic Acid | 9 | 0.0 |
Dose-Response Relationship, Drug | 120 | 1.0 |
Half-Life | 60 | 10.0 |
Isoenzymes/antagonists & inhibitors/chemistry/metabolism | 2 | 50.0 |
Lymphocytes/enzymology | 2 | 2.0 |
Oxidoreductases, N-Demethylating/antagonists & | 2 | 66.0 |
Aryl Hydrocarbon Hydroxylases/chemistry/*metabolism | 2 | 100.0 |
Catalysis | 39 | 4.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 14 | 77.0 |
Rats, Sprague-Dawley | 53 | 2.0 |
Substrate Specificity/physiology | 3 | 13.0 |
Cyclophosphamide/*pharmacology | 2 | 15.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*metabolism | 11 | 44.0 |
Dexamethasone/*pharmacology | 7 | 3.0 |
Drug Combinations | 12 | 2.0 |
Enzyme Activation/drug effects | 15 | 1.0 |
Enzyme Induction/drug effects | 58 | 15.0 |
Hepatocytes/*drug effects/enzymology | 8 | 57.0 |
Oxidoreductases, N-Demethylating/biosynthesis/*metabolism | 3 | 60.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 39 | 0.0 |
Enzyme Induction | 46 | 7.0 |
Enzyme Inhibitors/metabolism | 4 | 1.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 32 | 38.0 |
Drug Evaluation, Preclinical/methods | 3 | 9.0 |
Enzyme Induction/drug effects/physiology | 4 | 26.0 |
Hepatocytes/drug effects/*enzymology | 6 | 54.0 |
Pharmaceutical Preparations/metabolism | 10 | 30.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 8 | 5.0 |
Receptors, Steroid/*metabolism | 6 | 11.0 |
Cytochrome P-450 Enzyme System/*isolation & purification/metabolism | 2 | 100.0 |
Caco-2 Cells | 28 | 8.0 |
Coumarins/metabolism | 7 | 28.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*biosynthesis | 2 | 66.0 |
Hepatocytes/drug effects/enzymology | 4 | 40.0 |
Paclitaxel/metabolism | 2 | 25.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 36 | 52.0 |
DNA Primers | 43 | 0.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
Enzyme Induction/*drug effects | 5 | 29.0 |
Gene Expression Regulation, Enzymologic/drug effects | 4 | 2.0 |
Phenobarbital/pharmacology | 23 | 37.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 7 | 5.0 |
Receptors, Retinoic Acid/metabolism | 3 | 3.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Hepatocytes/*enzymology | 7 | 46.0 |
Omeprazole/pharmacology | 3 | 25.0 |
RNA, Messenger/*analysis | 5 | 1.0 |
Sensitivity and Specificity | 21 | 0.0 |
Blotting, Western | 48 | 0.0 |
Kidney/*enzymology | 3 | 4.0 |
Microsomes/metabolism | 13 | 10.0 |
Testosterone/metabolism | 46 | 35.0 |
Algorithms | 23 | 6.0 |
Cholesterol/blood | 2 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 3 | 0.0 |
Sex Factors | 16 | 1.0 |
Triglycerides/blood | 3 | 0.0 |
*Beverages | 25 | 55.0 |
*Citrus paradisi | 5 | 71.0 |
*Food-Drug Interactions | 18 | 81.0 |
Apoptosis/drug effects/*physiology | 3 | 1.0 |
DNA/drug effects/*metabolism | 2 | 40.0 |
DNA Fragmentation/drug effects | 3 | 3.0 |
DNA Topoisomerases, Type I/*metabolism | 2 | 7.0 |
Enzyme Inhibitors/*pharmacology | 67 | 9.0 |
Reactive Oxygen Species/*metabolism | 4 | 2.0 |
Staurosporine/*pharmacology | 2 | 10.0 |
Tumor Cells, Cultured | 65 | 0.0 |
Cross-Over Studies | 107 | 17.0 |
Double-Blind Method | 45 | 2.0 |
Itraconazole/blood/*pharmacology | 4 | 100.0 |
Depressive Disorder/*complications/drug therapy | 2 | 66.0 |
Tamoxifen/*pharmacology | 2 | 3.0 |
Hydrocortisone/*analogs & derivatives/urine | 7 | 46.0 |
Immunosuppressive Agents/administration & dosage/blood/*pharmacokinetics | 3 | 37.0 |
Rifampin/administration & dosage/*pharmacology | 3 | 75.0 |
Carboxylesterase | 2 | 5.0 |
Carboxylic Ester Hydrolases/metabolism | 2 | 10.0 |
Oxidoreductases, N-Demethylating/metabolism | 18 | 33.0 |
Dextromethorphan/metabolism | 3 | 27.0 |
Ethanolamines/metabolism | 5 | 27.0 |
Macaca mulatta | 3 | 0.0 |
Species Specificity | 49 | 1.0 |
Anti-Infective Agents/*pharmacology | 3 | 9.0 |
Chromatography, High Pressure Liquid | 161 | 9.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 44 | 62.0 |
Microsomes, Liver/drug effects/enzymology | 40 | 40.0 |
Recombinant Proteins/antagonists & inhibitors | 8 | 16.0 |
*Steroid 16-alpha-Hydroxylase | 57 | 30.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Anti-Bacterial Agents/*adverse effects | 2 | 16.0 |
Electrocardiography/drug effects | 8 | 25.0 |
Analysis of Variance | 28 | 1.0 |
Drug Synergism | 11 | 0.0 |
Pilot Projects | 6 | 0.0 |
Statistics, Nonparametric | 11 | 1.0 |
Databases, Factual | 3 | 1.0 |
Enzyme Inhibitors/*chemistry/*pharmacology | 3 | 20.0 |
Quantitative Structure-Activity Relationship | 5 | 16.0 |
Isoenzymes/chemistry/metabolism | 5 | 17.0 |
Models, Molecular | 26 | 0.0 |
Models, Theoretical | 2 | 1.0 |
Gene Expression Regulation, Enzymologic/*physiology | 4 | 4.0 |
Oxidoreductases, N-Demethylating/*genetics | 8 | 18.0 |
Steroid Hydroxylases/*genetics | 3 | 3.0 |
Anticonvulsants/*pharmacokinetics | 6 | 60.0 |
Antineoplastic Agents/metabolism | 2 | 11.0 |
Clinical Trials, Phase I | 2 | 3.0 |
Dogs | 25 | 2.0 |
Drug Design | 6 | 1.0 |
Drug Evaluation, Preclinical | 7 | 4.0 |
*Drug Resistance, Multiple | 2 | 1.0 |
Antineoplastic Agents, Phytogenic/*pharmacokinetics | 2 | 22.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Combined Modality Therapy | 6 | 0.0 |
Disease Progression | 3 | 0.0 |
Mixed Function Oxygenases/*metabolism | 86 | 61.0 |
Prodrugs/*pharmacokinetics | 2 | 18.0 |
Seizures/complications/drug therapy | 2 | 66.0 |
Injections, Intramuscular | 2 | 1.0 |
Long QT Syndrome/chemically induced | 2 | 66.0 |
Nausea/chemically induced | 3 | 10.0 |
Piperazines/adverse effects/pharmacokinetics/*therapeutic use | 2 | 66.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 20 | 57.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 15 | 78.0 |
Organ Transplantation | 2 | 16.0 |
Rhabdomyolysis/*chemically induced | 5 | 100.0 |
Risk Assessment | 8 | 0.0 |
Simvastatin/*adverse effects/therapeutic use | 3 | 100.0 |
Antipsychotic Agents/metabolism/*therapeutic use | 2 | 100.0 |
Biological Transport | 12 | 0.0 |
Carbon Radioisotopes | 5 | 5.0 |
Intestinal Absorption | 15 | 10.0 |
P-Glycoprotein/metabolism | 13 | 20.0 |
Permeability | 3 | 1.0 |
Nutritional Requirements | 2 | 6.0 |
*Vitamin D/administration & dosage/physiology | 2 | 66.0 |
*Vitamin D Deficiency/epidemiology/prevention & control | 2 | 66.0 |
Acetylation | 2 | 0.0 |
Carcinoma, Hepatocellular | 4 | 1.0 |
Gene Expression/drug effects | 8 | 1.0 |
Glucocorticoids/pharmacology | 7 | 5.0 |
Hela Cells | 3 | 0.0 |
Hepatocytes/cytology/drug effects/*metabolism | 3 | 37.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Pharmacokinetics | 16 | 44.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
Receptors, Cytoplasmic and Nuclear/*genetics/metabolism | 3 | 10.0 |
Prevalence | 2 | 0.0 |
Enzyme Inhibitors/administration & dosage/*pharmacology | 6 | 37.0 |
Microsomes, Liver/*drug effects | 2 | 66.0 |
Mutation | 17 | 0.0 |
Steroid Hydroxylases/*metabolism | 13 | 40.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 11 | 28.0 |
Oxidoreductases, N-Demethylating/biosynthesis/*genetics | 4 | 50.0 |
Food-Drug Interactions | 19 | 65.0 |
Case-Control Studies | 14 | 0.0 |
Odds Ratio | 2 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
Prostatic Neoplasms/*diagnosis/*genetics | 2 | 28.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics | 6 | 42.0 |
Enterocytes/enzymology/*metabolism | 3 | 100.0 |
Enzyme Inhibitors/blood | 2 | 18.0 |
Exons/*genetics | 2 | 0.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
Genes, MDR/*genetics | 7 | 21.0 |
Japan | 6 | 0.0 |
Mixed Function Oxygenases/biosynthesis/genetics | 5 | 50.0 |
Mutation/*genetics | 5 | 0.0 |
P-Glycoprotein/biosynthesis/genetics | 2 | 22.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Caffeine/metabolism | 4 | 14.0 |
Cytochrome P-450 Enzyme System/*physiology | 33 | 55.0 |
Liver/*enzymology | 32 | 7.0 |
Mephenytoin/metabolism | 2 | 12.0 |
Sparteine/metabolism | 2 | 33.0 |
Diet | 2 | 0.0 |
Microsomes, Liver/enzymology | 81 | 36.0 |
Antineoplastic Agents/*pharmacology | 11 | 1.0 |
Mixed Function Oxygenases/*biosynthesis/genetics | 6 | 66.0 |
RNA, Messenger/analysis | 20 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*agonists | 3 | 17.0 |
Receptors, Steroid/*agonists | 2 | 100.0 |
Insects/cytology | 2 | 16.0 |
Mass Fragmentography | 24 | 11.0 |
Microsomes, Liver/*metabolism | 75 | 43.0 |
*Monoterpenes | 5 | 50.0 |
Isoenzymes/antagonists & inhibitors | 10 | 24.0 |
Microsomes, Liver/drug effects/metabolism | 24 | 51.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 5 | 16.0 |
Aged, 80 and over | 29 | 0.0 |
Child, Preschool | 28 | 0.0 |
Cytochrome P-450 Enzyme System/*analysis | 5 | 26.0 |
Immunohistochemistry | 18 | 0.0 |
Infant | 22 | 0.0 |
Isoenzymes/*metabolism | 37 | 12.0 |
Baculoviridae/genetics | 8 | 4.0 |
Biological Markers/analysis | 2 | 0.0 |
Microsomes, Liver/*enzymology/metabolism | 15 | 51.0 |
Recombinant Proteins/biosynthesis | 5 | 1.0 |
Duodenum/enzymology | 2 | 25.0 |
Gene Expression Regulation, Enzymologic | 20 | 2.0 |
Intestine, Small/*enzymology | 6 | 30.0 |
Mutagenesis | 6 | 0.0 |
Cell Culture Techniques | 7 | 1.0 |
Flavonoids/*pharmacology | 6 | 7.0 |
Anti-Ulcer Agents/*pharmacokinetics | 5 | 83.0 |
Antifungal Agents/*pharmacology | 13 | 26.0 |
Fluconazole/*pharmacology | 3 | 20.0 |
Omeprazole/*pharmacokinetics | 4 | 57.0 |
Drug Administration Schedule | 19 | 2.0 |
*Drug Interactions | 14 | 60.0 |
English Abstract | 34 | 0.0 |
*Pharmacogenetics | 5 | 10.0 |
Polymorphism, Genetic | 31 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cytochromes b5/*metabolism | 4 | 66.0 |
Escherichia coli | 7 | 1.0 |
NADPH-Ferrihemoprotein Reductase/*metabolism | 2 | 33.0 |
Drug Monitoring | 6 | 13.0 |
Germany | 5 | 1.0 |
*Hypericum | 6 | 66.0 |
Mixed Function Oxygenases/*biosynthesis | 12 | 60.0 |
*Phytotherapy | 5 | 5.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/metabolism | 4 | 36.0 |
Pharmaceutical Preparations/*metabolism | 31 | 34.0 |
International Normalized Ratio | 2 | 6.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 29 | 24.0 |
European Continental Ancestry Group | 15 | 2.0 |
Mixed Function Oxygenases/*genetics/metabolism | 9 | 21.0 |
Hydrocortisone/urine | 3 | 25.0 |
Insulin-Like Growth Factor I/metabolism | 2 | 1.0 |
Liver/*drug effects/enzymology | 8 | 18.0 |
Calcium Channel Blockers/metabolism | 5 | 71.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Membrane Proteins/genetics/metabolism | 2 | 1.0 |
Microfilament Proteins/metabolism | 2 | 2.0 |
Verapamil/metabolism | 2 | 50.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 31 | 63.0 |
Immunosuppressive Agents/*metabolism | 2 | 16.0 |
Mixed Function Oxygenases/antagonists & inhibitors | 20 | 68.0 |
P-Glycoprotein/antagonists & inhibitors | 4 | 40.0 |
Spectrometry, Mass, Electrospray Ionization | 7 | 7.0 |
Subcellular Fractions/metabolism | 3 | 0.0 |
Anti-Bacterial Agents/pharmacology | 13 | 11.0 |
Binding Sites/physiology | 3 | 1.0 |
Hydroxylation/drug effects | 15 | 41.0 |
Mutagenesis, Site-Directed | 15 | 0.0 |
Oxidation-Reduction/drug effects | 7 | 8.0 |
Substrate Specificity/genetics | 2 | 4.0 |
Troleandomycin/pharmacology | 42 | 72.0 |
COS Cells | 11 | 0.0 |
Microsomes, Liver/chemistry/metabolism | 2 | 50.0 |
*Taxoids | 12 | 21.0 |
Protein Binding/drug effects | 2 | 0.0 |
Biological Transport/drug effects | 6 | 2.0 |
Calcium Channel Blockers/pharmacology | 7 | 7.0 |
LLC-PK1 Cells | 4 | 11.0 |
Swine | 28 | 2.0 |
Tissue Distribution | 25 | 0.0 |
Verapamil/pharmacology | 10 | 11.0 |
Blood Pressure/drug effects | 7 | 1.0 |
Predictive Value of Tests | 14 | 0.0 |
Regional Blood Flow | 2 | 1.0 |
Cytochrome P-450 Enzyme System/chemistry/*genetics | 2 | 25.0 |
DNA Mutational Analysis | 4 | 0.0 |
Exons | 6 | 0.0 |
Polymerase Chain Reaction | 39 | 0.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 17 | 60.0 |
Diltiazem/pharmacology | 3 | 21.0 |
Erythromycin/pharmacology | 7 | 43.0 |
Hypericum/*metabolism | 2 | 100.0 |
Anticonvulsants/*pharmacology | 7 | 35.0 |
Carbamazepine/*pharmacology | 5 | 62.0 |
Cytochrome P-450 Enzyme System/biosynthesis | 6 | 31.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Intestines/*metabolism | 7 | 9.0 |
P-Glycoprotein/*genetics | 3 | 6.0 |
Diclofenac/metabolism | 3 | 21.0 |
Recombinant Proteins/genetics/metabolism | 21 | 3.0 |
Warfarin/metabolism | 5 | 33.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/metabolism | 4 | 57.0 |
Omeprazole/*analogs & derivatives/*metabolism | 3 | 100.0 |
Enzyme Activation | 14 | 0.0 |
Enzyme Inhibitors/chemistry | 2 | 11.0 |
Enzyme Stability | 5 | 2.0 |
Furans/*pharmacology | 2 | 16.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors | 3 | 27.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/physiology | 3 | 100.0 |
Drug Resistance, Viral | 3 | 5.0 |
*HIV-1 | 4 | 0.0 |
Mixed Function Oxygenases/antagonists & inhibitors/physiology | 2 | 100.0 |
Kidney Transplantation/immunology | 2 | 3.0 |
Mixed Function Oxygenases/immunology | 3 | 60.0 |
Steroid Hydroxylases/immunology | 2 | 66.0 |
Administration, Oral | 65 | 6.0 |
Introns | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 8 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
Sequence Analysis, DNA | 9 | 0.0 |
Variation (Genetics)/*genetics | 4 | 1.0 |
DNA, Complementary/genetics | 17 | 0.0 |
Insects | 13 | 7.0 |
Oxidoreductases, N-Demethylating/*metabolism | 32 | 39.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors | 8 | 53.0 |
NADP/metabolism | 14 | 11.0 |
Cimetidine/pharmacology | 4 | 18.0 |
Disulfiram/pharmacology | 2 | 22.0 |
Ditiocarb/pharmacology | 3 | 17.0 |
Pyrazoles/pharmacology | 5 | 10.0 |
Chromatography, Liquid | 10 | 8.0 |
Cyclosporine/pharmacology | 10 | 4.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
Mixed Function Oxygenases/biosynthesis/*metabolism | 3 | 50.0 |
P-Glycoprotein/*metabolism | 14 | 17.0 |
Spectrum Analysis, Mass | 35 | 6.0 |
Hydrogen-Ion Concentration | 7 | 0.0 |
NADP/*physiology | 2 | 40.0 |
Reproducibility of Results | 27 | 1.0 |
Sex Characteristics | 9 | 1.0 |
Steroid 16-alpha-Hydroxylase | 7 | 50.0 |
Statistics | 11 | 2.0 |
DNA, Complementary/metabolism | 16 | 1.0 |
Imidazoles/pharmacokinetics/*pharmacology | 3 | 60.0 |
Isoenzymes/antagonists & inhibitors/genetics/metabolism | 6 | 42.0 |
Dealkylation | 30 | 52.0 |
Steroid Hydroxylases/antagonists & inhibitors/*metabolism | 4 | 44.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 4 | 26.0 |
Enzyme Inhibitors/metabolism/pharmacology | 6 | 31.0 |
Isoenzymes/biosynthesis/genetics/metabolism | 4 | 14.0 |
Rats, Long-Evans | 2 | 4.0 |
Spectrometry, Fluorescence | 5 | 1.0 |
Hypnotics and Sedatives/administration & dosage/blood/*pharmacokinetics | 2 | 100.0 |
Liver Function Tests | 4 | 2.0 |
Midazolam/administration & dosage/blood/*pharmacokinetics | 3 | 60.0 |
Amides/*metabolism | 2 | 33.0 |
Microsomes, Liver/enzymology/metabolism | 31 | 46.0 |
Drug Interactions/physiology | 11 | 33.0 |
Herb-Drug Interactions | 6 | 75.0 |
Lymphocytes/drug effects/metabolism | 2 | 6.0 |
Ritonavir/pharmacology | 6 | 50.0 |
Single-Blind Method | 3 | 1.0 |
Drug Stability | 3 | 1.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 28 | 66.0 |
Psoralens/chemistry/*pharmacology | 2 | 100.0 |
Enzyme Inhibitors/pharmacokinetics | 2 | 66.0 |
Molecular Conformation | 6 | 2.0 |
P-Glycoprotein/biosynthesis | 3 | 13.0 |
Rifampin/pharmacokinetics | 2 | 50.0 |
Mixed Function Oxygenases/*physiology | 18 | 58.0 |
Protein Isoforms | 6 | 0.0 |
Indinavir/pharmacology | 2 | 20.0 |
Magnetic Resonance Spectroscopy | 6 | 1.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/*metabolism | 6 | 66.0 |
Prospective Studies | 14 | 0.0 |
Psychiatric Status Rating Scales | 6 | 2.0 |
Schizophrenia/*blood/drug therapy | 2 | 10.0 |
Cytochrome P-450 Enzyme System/drug effects/*metabolism | 14 | 63.0 |
Mixed Function Oxygenases/drug effects/*metabolism | 5 | 83.0 |
Mammals | 3 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 9 | 8.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects | 4 | 80.0 |
Isoenzymes | 11 | 5.0 |
Amino Acid Sequence | 28 | 0.0 |
Conserved Sequence | 3 | 0.0 |
Evolution | 2 | 0.0 |
Isomerism | 8 | 3.0 |
Liver/metabolism | 29 | 3.0 |
Plasmids/genetics | 9 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 6 | 1.0 |
Rabbits | 38 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 53 | 0.0 |
Smoking/metabolism | 5 | 9.0 |
Steroids/*pharmacology | 2 | 10.0 |
Alcohol Drinking/metabolism | 2 | 25.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 7 | 43.0 |
Ethnic Groups | 7 | 2.0 |
P-Glycoprotein/drug effects/metabolism | 3 | 75.0 |
Receptors, Steroid/metabolism | 7 | 17.0 |
Electrocardiography/*drug effects | 3 | 50.0 |
Heart Rate/*drug effects | 2 | 6.0 |
Itraconazole/pharmacology | 5 | 83.0 |
Benzoquinones/*metabolism | 2 | 100.0 |
Cell Survival/drug effects | 12 | 1.0 |
Epoxy Compounds/*metabolism | 3 | 21.0 |
*Thiazolidinediones | 10 | 10.0 |
*Citrus | 31 | 73.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/physiology | 3 | 42.0 |
Actins/metabolism | 2 | 0.0 |
Antioxidants/pharmacology | 6 | 3.0 |
Arachidonic Acid/pharmacology | 2 | 4.0 |
Coculture Techniques | 4 | 0.0 |
Ferric Compounds/pharmacology | 2 | 18.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Hydrogen Peroxide/metabolism | 2 | 1.0 |
Lipid Peroxidation | 4 | 3.0 |
Nitrilotriacetic Acid/*analogs & derivatives/pharmacology | 2 | 66.0 |
Oxidative Stress | 2 | 0.0 |
Vitamin E/pharmacology | 2 | 6.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Caco-2 Cells/drug effects/*metabolism | 2 | 66.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Cytochrome P-450 CYP2E1/*metabolism | 6 | 10.0 |
Hepatocytes/*metabolism | 4 | 9.0 |
*Oxidative Stress | 2 | 0.0 |
Mutagenicity Tests/*methods | 5 | 19.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 2 | 12.0 |
Cytochrome P-450 CYP1A2/genetics | 2 | 18.0 |
Cytochrome P-450 CYP2D6 | 14 | 18.0 |
Mixed Function Oxygenases/genetics | 11 | 28.0 |
Mutagenicity Tests/methods | 2 | 16.0 |
NADPH-Ferrihemoprotein Reductase/*genetics/metabolism | 3 | 60.0 |
Salmonella typhimurium/*genetics | 3 | 42.0 |
Steroid Hydroxylases/genetics | 2 | 7.0 |
Breast Neoplasms/*drug therapy/enzymology | 2 | 33.0 |
DNA Primers/chemistry | 3 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Receptors, Estrogen/metabolism | 3 | 1.0 |
Microsomes, Liver/*drug effects/enzymology | 17 | 50.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 22 | 70.0 |
Molecular Weight | 6 | 0.0 |
Nifedipine/metabolism | 12 | 70.0 |
P-Glycoprotein/antagonists & inhibitors/*physiology | 2 | 40.0 |
Breast/*enzymology | 2 | 13.0 |
Gene Expression Regulation, Neoplastic | 7 | 0.0 |
RNA, Messenger/genetics | 11 | 0.0 |
Cytochromes b5/metabolism | 3 | 37.0 |
Heme/*metabolism | 3 | 14.0 |
Triazolam/*metabolism | 2 | 50.0 |
Anticonvulsants/metabolism/*pharmacology | 2 | 100.0 |
Enzyme Inhibitors/metabolism/*pharmacology | 2 | 11.0 |
Microsomes, Liver/drug effects/*enzymology/metabolism | 5 | 55.0 |
Rats, Wistar | 23 | 1.0 |
Microsomes, Liver/*drug effects/metabolism | 9 | 69.0 |
Clotrimazole/pharmacology | 3 | 23.0 |
Dexamethasone/pharmacology | 25 | 5.0 |
*Gene Expression/drug effects | 2 | 6.0 |
*Gene Expression Regulation | 2 | 0.0 |
Genetic Vectors | 10 | 0.0 |
Promoter Regions (Genetics)/genetics | 5 | 0.0 |
Anti-Anxiety Agents/*pharmacokinetics | 9 | 75.0 |
Gestational Age | 4 | 0.0 |
Infant, Newborn | 10 | 0.0 |
Injections, Intravenous | 20 | 3.0 |
Midazolam/*pharmacokinetics | 4 | 36.0 |
Anticholesteremic Agents/*pharmacokinetics | 4 | 80.0 |
Hypericum/*adverse effects | 3 | 100.0 |
Phytotherapy/*adverse effects | 3 | 100.0 |
Simvastatin/*pharmacokinetics | 2 | 100.0 |
GABA Modulators/pharmacokinetics | 3 | 100.0 |
Liver/drug effects/*enzymology | 6 | 15.0 |
Midazolam/pharmacokinetics | 7 | 58.0 |
Pupil/drug effects | 2 | 25.0 |
Butyrophenones/*metabolism | 2 | 100.0 |
Cloning, Molecular | 25 | 0.0 |
Histamine H1 Antagonists/*metabolism | 4 | 57.0 |
Oxygenases/antagonists & inhibitors/*metabolism | 3 | 50.0 |
Piperidines/*metabolism | 3 | 30.0 |
DNA, Complementary/biosynthesis | 12 | 21.0 |
Electrochemistry | 3 | 3.0 |
Animals, Genetically Modified | 2 | 0.0 |
Cricetulus | 6 | 1.0 |
Hamsters | 20 | 0.0 |
Linear Models | 5 | 1.0 |
Steroid 17-alpha-Hydroxylase/*genetics | 2 | 6.0 |
Chromatography, High Pressure Liquid/methods | 5 | 3.0 |
Enzyme Inhibitors/*metabolism | 6 | 7.0 |
H(+)-K(+)-Exchanging ATPase/*antagonists & inhibitors | 3 | 33.0 |
Antibiotics, Antitubercular/*pharmacology | 8 | 57.0 |
Immunochemistry | 4 | 1.0 |
Oxidoreductases, N-Demethylating/*biosynthesis | 4 | 22.0 |
Rifabutin/*pharmacology | 2 | 66.0 |
Rifampin/*pharmacology | 31 | 62.0 |
Triazolam/pharmacokinetics | 2 | 66.0 |
Anti-Anxiety Agents/*metabolism | 3 | 50.0 |
Intestines/metabolism | 8 | 7.0 |
Caco-2 Cells/drug effects/enzymology | 2 | 50.0 |
Hydroxytestosterones/metabolism | 4 | 50.0 |
P-Glycoprotein/*biosynthesis | 3 | 10.0 |
RNA, Messenger/biosynthesis | 19 | 1.0 |
Calcium Channel Blockers/*metabolism/pharmacokinetics | 2 | 66.0 |
Hepatocytes/metabolism | 10 | 12.0 |
Binding Sites | 33 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry | 5 | 41.0 |
Heme/chemistry | 3 | 14.0 |
Protein Conformation | 17 | 0.0 |
Spectrophotometry | 7 | 4.0 |
Binding Sites/drug effects/physiology | 2 | 7.0 |
Enzyme Inhibitors/chemistry/pharmacology | 3 | 12.0 |
Flow Cytometry | 4 | 0.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 17 | 36.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
China | 3 | 0.0 |
Cytochrome P-450 CYP1A2/*physiology | 4 | 57.0 |
Enzyme Inhibitors/chemistry/*pharmacology | 5 | 16.0 |
Midazolam/metabolism | 12 | 60.0 |
P-Glycoprotein/*antagonists & inhibitors/metabolism | 3 | 33.0 |
Vinblastine/metabolism | 2 | 33.0 |
Beverages | 14 | 53.0 |
Plant Extracts/pharmacology | 6 | 15.0 |
Aryl Hydrocarbon Hydroxylases/*chemistry/metabolism | 2 | 66.0 |
Steroid Hydroxylases/*chemistry/metabolism | 2 | 40.0 |
Swine, Miniature | 3 | 8.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 14 | 9.0 |
RNA, Messenger/genetics/metabolism | 13 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 10 | 18.0 |
Receptors, Steroid/*physiology | 10 | 50.0 |
Alkane 1-Monooxygenase | 5 | 16.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 6 | 20.0 |
Electrophoresis, Polyacrylamide Gel | 9 | 0.0 |
Steroid Hydroxylases/antagonists & inhibitors/metabolism | 6 | 66.0 |
Tolbutamide/metabolism | 3 | 20.0 |
Calcitriol/*pharmacology | 6 | 3.0 |
Cytochrome P-450 Enzyme System/genetics | 19 | 18.0 |
Gene Expression Regulation/drug effects | 7 | 0.0 |
Capsules | 4 | 9.0 |
Cytochrome P-450 Enzyme System/*drug effects | 7 | 53.0 |
Depressive Disorder/*drug therapy | 4 | 57.0 |
Aryl Hydrocarbon Hydroxylases/genetics/*metabolism | 4 | 16.0 |
Blotting, Southern | 3 | 0.0 |
Isoenzymes/genetics | 6 | 1.0 |
Liver | 2 | 3.0 |
Liver Neoplasms | 3 | 1.0 |
Pseudogenes | 2 | 1.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Microsomes/drug effects/enzymology | 5 | 26.0 |
*Thiophenes | 2 | 28.0 |
Calcium Channel Blockers/*adverse effects | 2 | 50.0 |
Long QT Syndrome/*chemically induced | 2 | 25.0 |
Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use | 2 | 100.0 |
Depressive Disorder/drug therapy | 4 | 66.0 |
Triazoles/*adverse effects/therapeutic use | 2 | 100.0 |
Dimerization | 4 | 0.0 |
Haplorhini | 9 | 3.0 |
Luciferases/genetics | 3 | 0.0 |
Receptors, Calcitriol/genetics/metabolism | 2 | 11.0 |
Retinoid X Receptors | 3 | 1.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Xenobiotics/*metabolism | 10 | 18.0 |
Cyclosporine/*pharmacokinetics | 5 | 45.0 |
Cytochrome P-450 Enzyme System/physiology | 13 | 50.0 |
Immunosuppressive Agents/*pharmacokinetics | 6 | 35.0 |
Mixed Function Oxygenases/physiology | 10 | 83.0 |
*Wine | 5 | 62.0 |
Diazepam/*pharmacokinetics | 4 | 100.0 |
Leukemia, Lymphocytic/metabolism | 3 | 75.0 |
Microsomes/enzymology | 19 | 18.0 |
Antipsychotic Agents/*pharmacokinetics | 2 | 33.0 |
Haloperidol/*pharmacokinetics | 2 | 100.0 |
Mixed Function Oxygenases/chemistry/*metabolism | 2 | 50.0 |
Receptors, Neurokinin-1/*antagonists & inhibitors | 2 | 50.0 |
Dialysis | 2 | 4.0 |
Steroid Hydroxylases/metabolism | 24 | 38.0 |
Gene Expression Profiling | 2 | 0.0 |
Hepatocytes/*drug effects/physiology | 2 | 66.0 |
RNA, Messenger/drug effects/metabolism | 3 | 2.0 |
Chlorpyrifos/*metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/chemistry/genetics/*metabolism | 2 | 25.0 |
Genome, Human | 3 | 0.0 |
Testosterone/*metabolism | 12 | 33.0 |
Survival Rate | 2 | 0.0 |
Testosterone/pharmacokinetics | 3 | 60.0 |
Transplantation, Heterologous | 2 | 0.0 |
Oxidoreductases, N-Demethylating | 2 | 100.0 |
Recombinant Proteins/pharmacokinetics | 2 | 11.0 |
Metabolic Clearance Rate | 36 | 10.0 |
Cytochrome P-450 CYP1A1/*antagonists & inhibitors | 2 | 33.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors | 2 | 13.0 |
Cytochrome P-450 CYP2E1/*antagonists & inhibitors | 3 | 50.0 |
Stilbenes/*pharmacology | 4 | 7.0 |
Psychomotor Performance/drug effects | 7 | 35.0 |
Terpenes/*metabolism | 2 | 40.0 |
Ifosfamide/*metabolism | 2 | 50.0 |
Automation | 2 | 3.0 |
Dimethyl Sulfoxide/pharmacology | 4 | 4.0 |
Drug Evaluation, Preclinical/*methods | 10 | 32.0 |
Software | 2 | 0.0 |
Solvents/pharmacology | 3 | 12.0 |
Micronucleus Tests | 2 | 4.0 |
Cell Count | 3 | 0.0 |
Cell Size | 3 | 1.0 |
Extracellular Matrix/*metabolism | 2 | 2.0 |
Antidepressive Agents, Second-Generation/*adverse effects | 2 | 66.0 |
*Alleles | 3 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 15 | 34.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
*Cell Differentiation | 3 | 1.0 |
Cell Division | 7 | 0.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/metabolism | 2 | 3.0 |
Down-Regulation | 5 | 0.0 |
Embryo/metabolism/pathology | 2 | 33.0 |
Embryo Loss/metabolism/pathology | 2 | 66.0 |
Endocardial Cushion Defects/embryology/*metabolism/pathology | 2 | 66.0 |
Endocardium/metabolism/pathology | 2 | 66.0 |
Gene Expression Regulation, Developmental | 4 | 0.0 |
Heart/drug effects/*embryology/*physiology | 2 | 66.0 |
Heart Diseases/congenital/metabolism/pathology | 2 | 66.0 |
High Mobility Group Proteins/genetics | 2 | 5.0 |
In Situ Hybridization | 5 | 0.0 |
*Morphogenesis | 2 | 10.0 |
Muscle Cells/drug effects/metabolism/*pathology | 2 | 66.0 |
Myocardium/metabolism/pathology | 2 | 6.0 |
Repressor Proteins/genetics/*metabolism | 2 | 1.0 |
Trans-Activators/genetics | 2 | 0.0 |
Benzoflavones/metabolism/*pharmacology | 2 | 66.0 |
Erythromycin/metabolism | 4 | 50.0 |
Estradiol/metabolism | 4 | 4.0 |
Methylation | 27 | 4.0 |
Tamoxifen/metabolism | 2 | 66.0 |
Dextrorphan/metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/*genetics | 4 | 36.0 |
Enzyme Induction/drug effects/genetics | 2 | 28.0 |
Mixed Function Oxygenases/*biosynthesis/*genetics | 3 | 100.0 |
Saccharomyces cerevisiae/enzymology | 2 | 3.0 |
Coumarins/*metabolism | 4 | 26.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Quinolines/*metabolism | 2 | 11.0 |
African Continental Ancestry Group/genetics | 7 | 2.0 |
European Continental Ancestry Group/genetics | 6 | 0.0 |
Liver/enzymology | 27 | 4.0 |
Polymorphism, Genetic/genetics | 6 | 0.0 |
*Sex Characteristics | 4 | 2.0 |
Antilipemic Agents/*pharmacology | 3 | 8.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 5 | 38.0 |
Cytochrome P-450 CYP2D6/metabolism | 23 | 57.0 |
Gemfibrozil/*pharmacology | 3 | 27.0 |
Anti-Inflammatory Agents/pharmacology | 3 | 5.0 |
Drug Resistance | 5 | 0.0 |
*Ketolides | 3 | 75.0 |
*Macrolides | 2 | 5.0 |
Anti-Bacterial Agents/pharmacokinetics | 4 | 80.0 |
Breath Tests | 14 | 19.0 |
Erythromycin/pharmacokinetics | 5 | 100.0 |
Cytochrome P-450 CYP2E1/genetics/metabolism | 2 | 16.0 |
Genetic Engineering | 3 | 3.0 |
Mixed Function Oxygenases/genetics/metabolism | 7 | 31.0 |
Mutagenicity Tests | 5 | 3.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 3 | 42.0 |
Salmonella typhimurium/drug effects/genetics | 2 | 14.0 |
Biopsy, Needle | 3 | 0.0 |
Reference Standards | 3 | 1.0 |
*Gene Expression | 5 | 0.0 |
Immunoblotting | 21 | 0.0 |
Liver/*embryology/enzymology | 2 | 40.0 |
*Aged | 3 | 7.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | 3 | 6.0 |
Phenols/*pharmacology | 3 | 8.0 |
Carcinogens/pharmacology | 3 | 3.0 |
Cytochrome P-450 CYP2E1/drug effects/*metabolism | 2 | 33.0 |
Hepatocytes/drug effects | 4 | 33.0 |
Lipid Peroxidation/*drug effects | 3 | 9.0 |
Models, Animal | 3 | 1.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 4 | 2.0 |
Hepatocytes/*drug effects/*enzymology | 5 | 71.0 |
Paclitaxel/analogs & derivatives/*pharmacology | 2 | 66.0 |
Epithelial Cells/*metabolism | 2 | 1.0 |
Genes, MDR/genetics | 2 | 18.0 |
Jejunum/*metabolism | 2 | 16.0 |
Mixed Function Oxygenases/biosynthesis | 6 | 42.0 |
Dihydropyridines/*pharmacology | 2 | 40.0 |
Nifedipine/pharmacology | 4 | 10.0 |
Oxidoreductases, N-Demethylating/biosynthesis | 4 | 50.0 |
RNA, Messenger/biosynthesis/drug effects | 8 | 13.0 |
Steroid Hydroxylases/biosynthesis | 2 | 22.0 |
Diltiazem/*pharmacology | 4 | 33.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/*metabolism | 5 | 100.0 |
Cytochrome P-450 CYP2D6/*genetics/metabolism | 2 | 8.0 |
Amino Acid Substitution | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry/genetics/*metabolism | 4 | 57.0 |
Cytosol/enzymology | 2 | 1.0 |
Mixed Function Oxygenases/*chemistry/genetics/*metabolism | 3 | 75.0 |
Phosphorylation | 2 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Staurosporine/pharmacology | 2 | 1.0 |
Great Britain | 2 | 0.0 |
Hepatoblastoma/pathology | 2 | 33.0 |
Phosphoproteins/pharmacology | 2 | 33.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Transcription Factors/pharmacology | 2 | 9.0 |
Up-Regulation | 3 | 0.0 |
Microsomes, Liver/chemistry/enzymology | 3 | 50.0 |
Cytochrome P-450 CYP1A1/drug effects/metabolism | 2 | 33.0 |
Cytochrome P-450 CYP1A2/drug effects/metabolism | 2 | 40.0 |
Mixed Function Oxygenases/drug effects/metabolism | 4 | 80.0 |
Simvastatin/*adverse effects | 3 | 100.0 |
Alprazolam/blood/*pharmacokinetics | 2 | 100.0 |
Anti-Anxiety Agents/blood/*pharmacokinetics | 2 | 40.0 |
Hydrocortisone/*analogs & derivatives/*urine | 5 | 38.0 |
Enzymes/*genetics/*metabolism | 2 | 100.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Hydroxysteroid Dehydrogenases/genetics/metabolism | 2 | 66.0 |
Citalopram/blood/*pharmacokinetics/pharmacology | 2 | 100.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 7 | 10.0 |
Macaca fascicularis | 10 | 3.0 |
Fluvoxamine/pharmacokinetics/pharmacology | 2 | 100.0 |
*Drug Monitoring | 3 | 15.0 |
Liver Transplantation | 3 | 5.0 |
Liver/*metabolism | 25 | 5.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
Carbamazepine/pharmacology | 3 | 50.0 |
Cholesterol/metabolism | 2 | 0.0 |
Phenytoin/pharmacology | 5 | 35.0 |
Ursodeoxycholic Acid/pharmacology | 2 | 66.0 |
Progesterone/metabolism | 4 | 5.0 |
Anticonvulsants/*metabolism | 3 | 37.0 |
Epoxy Compounds/metabolism | 2 | 25.0 |
ATP-Binding Cassette Transporters/*biosynthesis/genetics | 2 | 11.0 |
Cytochrome P-450 Enzyme System/*chemistry/*metabolism | 11 | 64.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Malondialdehyde/metabolism | 2 | 7.0 |
Microsomes, Liver/drug effects/enzymology/*metabolism | 10 | 55.0 |
Methadone/*metabolism | 3 | 100.0 |
Narcotics/*metabolism | 3 | 30.0 |
Antipsychotic Agents/*metabolism | 4 | 66.0 |
Cytochrome P-450 CYP1A2/physiology | 2 | 33.0 |
Cytochrome P-450 CYP2D6/physiology | 5 | 71.0 |
Steroid Hydroxylases/physiology | 3 | 50.0 |
Erythromycin/administration & dosage/*pharmacology | 4 | 80.0 |
Bayes Theorem | 3 | 5.0 |
Ketoconazole/administration & dosage/*pharmacology | 5 | 100.0 |
Oxidoreductases, N-Demethylating/drug effects/metabolism | 2 | 50.0 |
Oxidoreductases, N-Demethylating/physiology | 4 | 66.0 |
Rats, Inbred F344 | 8 | 2.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors | 4 | 57.0 |
Histamine H1 Antagonists/*pharmacology | 3 | 27.0 |
Steroid Hydroxylases/antagonists & inhibitors | 4 | 40.0 |
Antibodies, Monoclonal/pharmacology | 8 | 1.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 6 | 40.0 |
Mixed Function Oxygenases/immunology/*metabolism | 2 | 33.0 |
Omeprazole/analogs & derivatives/*metabolism | 2 | 100.0 |
Antimalarials/*pharmacokinetics | 3 | 75.0 |
Chloroguanide/*pharmacokinetics | 2 | 100.0 |
Triazines/metabolism | 2 | 50.0 |
Genetic Predisposition to Disease | 8 | 0.0 |
Sequence Alignment | 7 | 0.0 |
DNA | 5 | 0.0 |
Nuclear Proteins/metabolism | 3 | 0.0 |
Transcription Factor, Sp1/*physiology | 2 | 2.0 |
Antineoplastic Agents, Phytogenic/metabolism/*pharmacokinetics | 2 | 66.0 |
DNA Topoisomerases, Type I/antagonists & inhibitors | 2 | 8.0 |
Adverse Drug Reaction Reporting Systems | 2 | 18.0 |
Receptor, Serotonin, 5-HT1D | 2 | 33.0 |
Receptors, Serotonin/*drug effects | 2 | 22.0 |
Blood Proteins/metabolism | 7 | 3.0 |
Antiretroviral Therapy, Highly Active | 2 | 0.0 |
Cattle | 8 | 0.0 |
Cholesterol/biosynthesis | 2 | 13.0 |
Kidney/metabolism | 2 | 0.0 |
Mitochondria/metabolism | 2 | 0.0 |
Triazoles/*pharmacology | 3 | 23.0 |
Gene Expression/drug effects/immunology | 2 | 5.0 |
Intercellular Signaling Peptides and Proteins/*genetics | 2 | 3.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Mice, Inbred Strains | 5 | 0.0 |
Muscle, Skeletal/cytology/*physiology | 2 | 12.0 |
Myoblasts/cytology/drug effects/*physiology | 2 | 33.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Macrolides | 5 | 20.0 |
3T3 Cells | 4 | 0.0 |
Adenosine Triphosphate/metabolism | 3 | 0.0 |
Pravastatin/pharmacology | 3 | 33.0 |
Calibration | 6 | 4.0 |
Chromatography, High Pressure Liquid/*methods | 4 | 3.0 |
Spectrum Analysis, Mass/*methods | 3 | 7.0 |
Aflatoxin B1/metabolism | 2 | 25.0 |
Benzo(a)pyrene/pharmacology | 2 | 9.0 |
Cytochrome P-450 CYP1A1/metabolism | 16 | 24.0 |
Imidazoles/pharmacology | 2 | 0.0 |
NADPH-Ferrihemoprotein Reductase/metabolism | 7 | 30.0 |
Indicators and Reagents | 9 | 3.0 |
Recombinant Proteins/chemistry | 4 | 1.0 |
Hepatocytes/*drug effects/*metabolism | 2 | 40.0 |
Binding, Competitive | 11 | 0.0 |
Chlorzoxazone/metabolism | 4 | 20.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors/*metabolism | 3 | 100.0 |
Magnesium Chloride/pharmacology | 2 | 10.0 |
Cytochrome P-450 Enzyme System/isolation & purification/*metabolism | 2 | 33.0 |
Escherichia coli/enzymology | 2 | 3.0 |
Estradiol/*metabolism | 5 | 7.0 |
Bile Acids and Salts/*biosynthesis | 2 | 13.0 |
Cytochrome P-450 Enzyme System/genetics/*physiology | 6 | 54.0 |
Analgesics, Opioid/*metabolism | 4 | 80.0 |
Antidepressive Agents, Second-Generation/*metabolism | 3 | 100.0 |
DNA/biosynthesis | 3 | 0.0 |
Binding, Competitive/drug effects | 2 | 3.0 |
Thiocyanates/*pharmacology | 2 | 16.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/*metabolism | 4 | 30.0 |
Cytomegalovirus/*drug effects | 2 | 40.0 |
Indinavir/metabolism | 3 | 100.0 |
Cytochrome P-450 CYP2D6/genetics/*metabolism | 4 | 28.0 |
Insulin/blood | 2 | 0.0 |
Reference Values | 48 | 1.0 |
Cytochrome P-450 CYP2D6/genetics | 2 | 6.0 |
Gastrointestinal Agents/blood/*pharmacokinetics/pharmacology | 2 | 100.0 |
Benzimidazoles/pharmacology | 4 | 9.0 |
Psoralens/pharmacology | 4 | 44.0 |
Quercetin/pharmacology | 3 | 15.0 |
Radiation-Sensitizing Agents/pharmacology | 2 | 8.0 |
Hydrolysis | 4 | 0.0 |
Microsomes, Liver | 3 | 30.0 |
Drug Interactions/*physiology | 2 | 66.0 |
HIV Protease Inhibitors/*pharmacokinetics | 5 | 100.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*metabolism | 3 | 75.0 |
Microsomes, Liver/*drug effects/enzymology/metabolism | 3 | 75.0 |
Simvastatin/*metabolism | 3 | 100.0 |
Verapamil/*pharmacology | 2 | 6.0 |
Age Factors | 15 | 0.0 |
Immunoassay | 2 | 0.0 |
Intestines/*enzymology | 6 | 17.0 |
Methylprednisolone/*pharmacokinetics | 2 | 100.0 |
Prednisolone/*pharmacokinetics | 2 | 100.0 |
Midazolam/pharmacology | 9 | 100.0 |
Hepatocytes/enzymology | 3 | 20.0 |
Antihypertensive Agents/*pharmacokinetics | 4 | 66.0 |
Diclofenac/pharmacokinetics | 2 | 50.0 |
Losartan/*pharmacokinetics | 2 | 100.0 |
Receptors, Angiotensin/*antagonists & inhibitors | 3 | 3.0 |
Liver/drug effects/*metabolism | 6 | 8.0 |
Body Weight | 2 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/biosynthesis | 4 | 100.0 |
Mixed Function Oxygenases/antagonists & inhibitors/biosynthesis | 2 | 66.0 |
Omeprazole/therapeutic use | 2 | 28.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cell Line, Tumor | 18 | 0.0 |
HL-60 Cells | 3 | 0.0 |
K562 Cells | 2 | 0.0 |
Androstenedione/metabolism | 3 | 10.0 |
Cytochromes b5/genetics/*metabolism | 4 | 100.0 |
Lauric Acids/metabolism | 2 | 22.0 |
NADPH-Ferrihemoprotein Reductase/genetics/*metabolism | 4 | 40.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Chromans/*metabolism | 2 | 50.0 |
Hepatocytes/enzymology/metabolism | 2 | 50.0 |
Thiazoles/*metabolism | 6 | 46.0 |
Postmenopause | 3 | 1.0 |
Steryl-Sulfatase | 3 | 2.0 |
Enzyme Inhibitors | 2 | 2.0 |
Epithelial Cells/enzymology | 2 | 5.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 4 | 28.0 |
Toxicology/*methods | 2 | 28.0 |
Xenobiotics/toxicity | 2 | 25.0 |
Cytochrome P-450 Enzyme System/*genetics/physiology | 2 | 28.0 |
Immunosuppressive Agents/pharmacokinetics | 2 | 28.0 |
Kidney Transplantation | 4 | 3.0 |
Antifungal Agents/blood/*pharmacology | 3 | 75.0 |
Confidence Intervals | 7 | 2.0 |
Cytochrome P-450 Enzyme System/*immunology | 3 | 42.0 |
*Liver Transplantation | 5 | 3.0 |
Prognosis | 3 | 0.0 |
Survival Analysis | 3 | 0.0 |
Microsomes, Liver/drug effects | 4 | 66.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors | 3 | 33.0 |
Enzyme Inhibitors/pharmacokinetics/*pharmacology | 3 | 27.0 |
Anticholesteremic Agents/*therapeutic use | 2 | 3.0 |
Cell Fractionation | 2 | 0.0 |
Isoenzymes/*biosynthesis | 4 | 6.0 |
Necrosis | 2 | 0.0 |
Clofibrate/pharmacology | 4 | 19.0 |
Methylcholanthrene/pharmacology | 5 | 14.0 |
Biological Transport, Active | 8 | 4.0 |
*Models, Molecular | 5 | 4.0 |
Austria | 2 | 3.0 |
*HIV-1/drug effects | 2 | 16.0 |
Electrocardiography | 3 | 0.0 |
Long QT Syndrome/*chemically induced/complications | 2 | 100.0 |
Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors/genetics | 2 | 50.0 |
Epilepsy/drug therapy | 4 | 33.0 |
B-Lymphocytes/enzymology | 4 | 11.0 |
Coumarins/*pharmacokinetics | 2 | 100.0 |
*Flavonoids | 2 | 8.0 |
NADPH-Ferrihemoprotein Reductase/chemistry | 2 | 100.0 |
Steroid Hydroxylases/chemistry | 3 | 75.0 |
Isoenzymes/genetics/*metabolism | 8 | 8.0 |
Serotonin Antagonists/*pharmacology | 2 | 20.0 |
Alprazolam/administration & dosage/*pharmacokinetics | 2 | 66.0 |
*Pharmacokinetics | 10 | 23.0 |
Age Distribution | 2 | 0.0 |
Cohort Studies | 5 | 0.0 |
Incidence | 3 | 0.0 |
Probability | 3 | 0.0 |
Recombinant Proteins/antagonists & inhibitors/metabolism | 7 | 16.0 |
Phosphodiesterase Inhibitors/*metabolism | 2 | 66.0 |
Cytochrome P-450 Enzyme System/*drug effects/metabolism | 6 | 42.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Mixed Function Oxygenases/*drug effects/metabolism | 4 | 100.0 |
Chromosome Mapping | 4 | 0.0 |
DNA, Complementary | 24 | 1.0 |
*Gene Expression Regulation, Enzymologic/drug effects | 3 | 6.0 |
Mixed Function Oxygenases/antagonists & inhibitors/immunology/*metabolism | 4 | 80.0 |
Terfenadine/*metabolism | 2 | 100.0 |
Intestinal Absorption/*physiology | 3 | 12.0 |
Intestines/enzymology | 4 | 22.0 |
Pharmaceutical Preparations/chemistry/*metabolism | 2 | 66.0 |
Maternal-Fetal Exchange/drug effects | 2 | 50.0 |
Ritonavir/*administration & dosage | 2 | 28.0 |
Lipid Peroxidation/drug effects | 2 | 3.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Aging/*metabolism | 7 | 3.0 |
Histamine H1 Antagonists/blood/*pharmacokinetics | 3 | 100.0 |
Aspartate Aminotransferases/metabolism | 2 | 11.0 |
Cyclosporine/*pharmacology | 3 | 2.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors/metabolism | 2 | 18.0 |
Cytochrome P-450 CYP2E1/*antagonists & inhibitors/metabolism | 2 | 25.0 |
Cytochrome P-450 Enzyme System/biosynthesis/metabolism | 4 | 50.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Glutathione/metabolism | 3 | 1.0 |
Organ Specificity | 3 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Urea/metabolism | 2 | 4.0 |
Antibiotics, Antineoplastic/*metabolism | 2 | 28.0 |
GABA Modulators/pharmacology | 5 | 50.0 |
P-Glycoprotein/drug effects/*metabolism | 2 | 50.0 |
Testosterone/pharmacology | 2 | 3.0 |
Adenoviridae/genetics | 2 | 0.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Extracellular Space/metabolism | 2 | 3.0 |
Diabetes Complications | 2 | 1.0 |
P-Glycoprotein/*physiology | 4 | 18.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
Anti-Bacterial Agents/*adverse effects/therapeutic use | 2 | 33.0 |
Dopamine Agonists/*pharmacology | 2 | 16.0 |
Liver/cytology | 2 | 3.0 |
RNA/metabolism | 2 | 0.0 |
Aging/metabolism | 4 | 2.0 |
Cell Line, Transformed | 4 | 0.0 |
Microsomes/enzymology/metabolism | 3 | 17.0 |
Regression Analysis | 12 | 0.0 |
Immune Sera/pharmacology | 2 | 2.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 15 | 50.0 |
Solubility | 3 | 0.0 |
Asian Continental Ancestry Group/*genetics | 6 | 1.0 |
China/ethnology | 2 | 1.0 |
Exons/genetics | 4 | 0.0 |
Hydrocortisone/analogs & derivatives/urine | 3 | 50.0 |
Hepatocytes/*enzymology/metabolism | 3 | 60.0 |
Isoenzymes/genetics/metabolism | 12 | 8.0 |
Liver/enzymology/metabolism | 4 | 12.0 |
Methoxsalen/pharmacology | 3 | 37.0 |
Terpenes/pharmacology | 3 | 11.0 |
Felodipine/*pharmacokinetics | 3 | 100.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/metabolism | 3 | 100.0 |
Digoxin/pharmacokinetics | 4 | 50.0 |
*Plants, Medicinal | 8 | 11.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 7 | 46.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Infusions, Intravenous | 8 | 1.0 |
Oxidoreductases, N-Demethylating/drug effects/*metabolism | 4 | 100.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics/metabolism | 2 | 66.0 |
African Continental Ancestry Group | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Estrogens/metabolism | 2 | 2.0 |
Mixed Function Oxygenases/chemistry | 4 | 57.0 |
Mixed Function Oxygenases/*genetics/*metabolism | 5 | 27.0 |
P-Glycoprotein/*genetics/*metabolism | 2 | 66.0 |
Acetonitriles/pharmacology | 2 | 50.0 |
Ethanol/pharmacology | 4 | 6.0 |
Glucuronosyltransferase/*metabolism | 2 | 3.0 |
Methanol/pharmacology | 2 | 18.0 |
Solvents/*pharmacology | 2 | 20.0 |
Haloperidol/*analogs & derivatives/metabolism | 2 | 100.0 |
Methadone/*pharmacokinetics | 2 | 100.0 |
Calcium Channel Blockers/*pharmacology | 2 | 5.0 |
Tritium | 4 | 1.0 |
Colchicine/*pharmacology | 2 | 18.0 |
Protein Isoforms/metabolism | 4 | 2.0 |
Microsomes/drug effects/*enzymology | 2 | 50.0 |
Fetus/enzymology | 3 | 11.0 |
Microsomes | 5 | 35.0 |
Liver/*metabolism/pathology | 2 | 6.0 |
Proteins/metabolism | 2 | 0.0 |
Spodoptera | 4 | 1.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Steroid Hydroxylases/*antagonists & inhibitors | 2 | 28.0 |
Chromatography, Liquid/*methods | 3 | 18.0 |
Glucose/metabolism | 2 | 0.0 |
Delayed-Action Preparations | 3 | 2.0 |
*Flavanones | 5 | 20.0 |
Flavonoids/pharmacology | 3 | 0.0 |
Estrogens/*pharmacology | 2 | 2.0 |
Gene Expression/*drug effects | 4 | 1.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 9 | 18.0 |
Mutagens/*toxicity | 5 | 4.0 |
Plasmids | 7 | 0.0 |
Brain Neoplasms/pathology/*radiotherapy/*therapy | 2 | 100.0 |
Feasibility Studies | 2 | 0.0 |
Glioblastoma/pathology/*radiotherapy/*therapy | 2 | 100.0 |
Hyperthermia, Induced/adverse effects/instrumentation/*methods | 2 | 100.0 |
Mixed Function Oxygenases/*chemistry/*metabolism | 3 | 60.0 |
Cytochrome P-450 Enzyme System/*drug effects/*genetics | 2 | 100.0 |
GABA Modulators/metabolism | 2 | 50.0 |
Receptors, Cytoplasmic and Nuclear/*biosynthesis/genetics | 2 | 20.0 |
Transcription Factors/*biosynthesis/genetics | 2 | 2.0 |
Benzoflavones/metabolism | 2 | 33.0 |
Losartan/metabolism | 2 | 100.0 |
*Models, Biological | 7 | 3.0 |
Blotting, Northern | 8 | 0.0 |
Oxidoreductases, N-Demethylating/*genetics/metabolism | 2 | 28.0 |
*Drug Design | 4 | 4.0 |
Pharmacology | 2 | 50.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacokinetics | 4 | 66.0 |
Pyrroles/*pharmacokinetics | 2 | 100.0 |
Cytosol/enzymology/*metabolism | 2 | 66.0 |
Cysteine Proteinase Inhibitors/*pharmacokinetics | 2 | 100.0 |
Alkylation | 5 | 7.0 |
B-Lymphocytes/enzymology/metabolism | 2 | 22.0 |
Oxygen/metabolism | 2 | 0.0 |
Oncorhynchus mykiss | 2 | 12.0 |
Glucuronosyltransferase/*antagonists & inhibitors | 2 | 66.0 |
Milk Thistle/*chemistry | 2 | 100.0 |
Silymarin/*pharmacology | 3 | 17.0 |
Quinidine/metabolism | 2 | 28.0 |
Breath Tests/methods | 3 | 50.0 |
Carbon Radioisotopes/diagnostic use | 5 | 8.0 |
P-Glycoprotein/genetics/*metabolism | 2 | 10.0 |
Transfection/methods | 2 | 1.0 |
Simvastatin/*analogs & derivatives/*blood | 2 | 100.0 |
Asian Continental Ancestry Group/genetics | 5 | 1.0 |
Mixed Function Oxygenases/biosynthesis/*genetics | 4 | 36.0 |
Retrospective Studies | 4 | 0.0 |
Plant Extracts/*pharmacology | 10 | 13.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 5 | 17.0 |
Liver/cytology/*drug effects/enzymology | 3 | 25.0 |
Plants, Medicinal/*chemistry | 2 | 11.0 |
Precipitin Tests | 2 | 0.0 |
Saccharomyces cerevisiae/genetics | 4 | 0.0 |
Anti-Arrhythmia Agents/*pharmacokinetics | 3 | 50.0 |
Microsomes/drug effects/enzymology/metabolism | 2 | 50.0 |
beta-Naphthoflavone/pharmacology | 4 | 13.0 |
Cytochrome P-450 Enzyme System/drug effects/genetics/*metabolism | 2 | 66.0 |
Liver/cytology/drug effects/metabolism | 2 | 16.0 |
Oxidoreductases/metabolism | 4 | 5.0 |
Calcium Channel Blockers/pharmacokinetics | 4 | 66.0 |
Diltiazem/pharmacokinetics | 2 | 100.0 |
Fluoxetine/pharmacokinetics | 3 | 100.0 |
Serotonin Uptake Inhibitors/pharmacokinetics | 2 | 66.0 |
Anti-Infective Agents/*pharmacokinetics | 3 | 100.0 |
Immunosuppressive Agents/blood/*pharmacokinetics | 2 | 22.0 |
Tacrolimus/blood/*pharmacokinetics | 3 | 50.0 |
Liver/drug effects/enzymology | 11 | 16.0 |
Omeprazole/*analogs & derivatives/pharmacology | 2 | 66.0 |
Sulfoxides/pharmacology | 2 | 33.0 |
P-Glycoprotein/*biosynthesis/genetics | 2 | 15.0 |
Psychotic Disorders/*drug therapy | 2 | 66.0 |
Schizophrenia/*drug therapy | 2 | 6.0 |
*Sequence Homology, Amino Acid | 2 | 2.0 |
Crystallography, X-Ray | 3 | 0.0 |
Hydrogen Bonding | 2 | 1.0 |
Progesterone/*metabolism | 3 | 8.0 |
Erythromycin/diagnostic use | 3 | 42.0 |
Cytochrome P-450 CYP1A2/biosynthesis | 4 | 33.0 |
Esophagus/*enzymology | 2 | 50.0 |
Intestinal Mucosa/*enzymology | 2 | 10.0 |
*Transcription Factors | 4 | 0.0 |
Colonic Neoplasms | 2 | 1.0 |
Propafenone/*metabolism | 2 | 100.0 |
Serotonin Uptake Inhibitors/*pharmacology | 6 | 20.0 |
Antipsychotic Agents/*adverse effects/therapeutic use | 3 | 25.0 |
Biotransformation/drug effects | 6 | 20.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/drug effects/metabolism | 2 | 100.0 |
Anti-HIV Agents/pharmacology | 3 | 6.0 |
Liver/cytology/*drug effects/metabolism | 3 | 18.0 |
Ritonavir/*adverse effects | 2 | 100.0 |
Vomiting/chemically induced | 2 | 11.0 |
Hypnotics and Sedatives/blood/*pharmacokinetics | 5 | 83.0 |
Triazolam/blood/*pharmacokinetics | 4 | 80.0 |
Citrus/*chemistry | 5 | 71.0 |
Plant Extracts/chemistry/pharmacology | 3 | 30.0 |
Tritium/diagnostic use | 3 | 2.0 |
Anti-Ulcer Agents/metabolism | 3 | 60.0 |
Anti-Arrhythmia Agents/metabolism | 2 | 100.0 |
Liver/enzymology/*metabolism | 3 | 8.0 |
*Linkage (Genetics) | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
*Transcription, Genetic | 9 | 0.0 |
Individuality | 2 | 9.0 |
Substrate Specificity/drug effects/genetics | 2 | 100.0 |
Steroid Hydroxylases/analysis | 2 | 100.0 |
Tretinoin/*metabolism | 4 | 9.0 |
Dealkylation/drug effects | 3 | 100.0 |
Mixed Function Oxygenases/biosynthesis/metabolism | 2 | 66.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Beverages/*analysis | 2 | 66.0 |
Antineoplastic Agents, Phytogenic/*metabolism | 2 | 20.0 |
CHO Cells | 5 | 0.0 |
Metabolic Detoxication, Drug | 13 | 15.0 |
Antidepressive Agents/*pharmacology | 2 | 7.0 |
Bicyclo Compounds | 3 | 50.0 |
Phloroglucinol/analogs & derivatives | 3 | 50.0 |
Erythromycin/*pharmacology | 12 | 57.0 |
Fluvoxamine/pharmacology | 9 | 64.0 |
Citrus/*metabolism | 3 | 60.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 8 | 22.0 |
Cytosol/metabolism | 2 | 0.0 |
Microsomes/*enzymology | 8 | 18.0 |
Antifungal Agents/*pharmacokinetics | 2 | 100.0 |
Itraconazole/*pharmacokinetics | 2 | 100.0 |
*Intestinal Absorption | 3 | 8.0 |
Intestine, Small/*metabolism | 4 | 15.0 |
Biomechanics | 2 | 1.0 |
Blood Platelets/cytology | 2 | 8.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Cell Communication/*physiology | 2 | 3.0 |
*Cell Physiology | 2 | 15.0 |
Endothelium, Vascular/*cytology/physiology | 2 | 10.0 |
Hematopoiesis/*physiology | 2 | 2.0 |
Inflammation/pathology | 2 | 3.0 |
Integrins | 2 | 40.0 |
Leukocytes/*cytology/physiology | 2 | 50.0 |
Selectins | 2 | 66.0 |
Thrombosis/pathology | 2 | 14.0 |
Neoplasms/*drug therapy | 3 | 2.0 |
Antineoplastic Agents, Phytogenic/*pharmacokinetics/therapeutic use | 2 | 100.0 |
Least-Squares Analysis | 2 | 5.0 |
*Bacterial Proteins | 2 | 1.0 |
Carbon Monoxide/chemistry | 2 | 50.0 |
Mixed Function Oxygenases/*chemistry | 2 | 28.0 |
Pressure | 2 | 1.0 |
Temperature | 2 | 0.0 |
Cytochrome P-450 CYP2D6/*physiology | 4 | 66.0 |
Dextromethorphan/*metabolism | 3 | 75.0 |
Liver/drug effects/enzymology/metabolism | 2 | 16.0 |
*Flavones | 2 | 28.0 |
Ketoconazole/*pharmacology | 6 | 23.0 |
Contraceptives, Oral/pharmacology | 2 | 11.0 |
Designer Drugs/*metabolism | 2 | 100.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Fluorouracil/*pharmacology | 3 | 7.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Models, Theoretical | 2 | 3.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Stomach Neoplasms/*drug therapy/*genetics | 2 | 100.0 |
Glutathione Transferase/genetics/metabolism | 2 | 1.0 |
Antibodies, Blocking/pharmacology | 5 | 5.0 |
Cyclooxygenase Inhibitors/*metabolism | 2 | 66.0 |
Amitriptyline/*metabolism | 2 | 50.0 |
Immunization | 2 | 0.0 |
Alkaline Phosphatase/metabolism | 3 | 2.0 |
Anti-Inflammatory Agents/*pharmacology | 2 | 2.0 |
Genes, Reporter/genetics | 4 | 1.0 |
Liver/cytology/drug effects/enzymology | 2 | 40.0 |
Transfection/genetics | 2 | 1.0 |
Antipsychotic Agents/blood/*pharmacokinetics | 2 | 33.0 |
Piperazines/blood/*pharmacokinetics | 2 | 100.0 |
Sulfones/metabolism | 2 | 50.0 |
Sulfoxides/metabolism | 3 | 75.0 |
Antitussive Agents/*metabolism | 2 | 100.0 |
Hypoglycemic Agents/*pharmacology | 2 | 4.0 |
Thiazoles/*pharmacology | 2 | 3.0 |
Antifungal Agents/*metabolism | 2 | 66.0 |
HIV Protease Inhibitors/*metabolism | 3 | 60.0 |
Ketoconazole/*metabolism | 2 | 100.0 |
Antineoplastic Agents, Phytogenic/metabolism | 2 | 66.0 |
P-Glycoprotein/*antagonists & inhibitors | 2 | 16.0 |
Oxidoreductases/*antagonists & inhibitors/metabolism | 2 | 100.0 |
*Artemisinins | 6 | 46.0 |
Heart/drug effects | 3 | 6.0 |
HIV Protease Inhibitors/administration & dosage/blood/*pharmacokinetics | 2 | 100.0 |
Nonlinear Dynamics | 3 | 12.0 |
Perfusion | 3 | 1.0 |
Anti-Bacterial Agents/*pharmacokinetics | 2 | 40.0 |
Phosphodiesterase Inhibitors/*pharmacokinetics | 2 | 100.0 |
Piperazines/*pharmacokinetics | 2 | 40.0 |
Isoenzymes/antagonists & inhibitors/biosynthesis/metabolism | 3 | 75.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Debrisoquin/metabolism | 2 | 20.0 |
HIV Protease Inhibitors/*pharmacology | 5 | 17.0 |
Indinavir/*metabolism | 2 | 66.0 |
Quinine/pharmacology | 3 | 23.0 |
Escherichia coli/genetics | 4 | 0.0 |
Excitatory Amino Acid Antagonists/pharmacology | 2 | 6.0 |
Culture Media | 3 | 0.0 |
Cyclophosphamide/*metabolism | 2 | 33.0 |
Fluorometry/methods | 2 | 22.0 |
Citrus | 2 | 66.0 |
*Diet | 2 | 0.0 |
Digestive System/*metabolism | 2 | 5.0 |
Flavonoids/metabolism | 2 | 22.0 |
Microsomes/drug effects/*metabolism | 2 | 66.0 |
Midazolam/metabolism/pharmacology | 3 | 100.0 |
Testosterone/metabolism/pharmacology | 2 | 66.0 |
NADP/pharmacology | 8 | 36.0 |
Benzoflavones/pharmacology | 9 | 18.0 |
Cytochrome P-450 CYP2E1/*genetics | 2 | 1.0 |
*Gene Expression Regulation, Enzymologic | 12 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
European Continental Ancestry Group/*genetics | 5 | 1.0 |
Monoamine Oxidase/*metabolism | 2 | 8.0 |
Diazepam/metabolism | 2 | 28.0 |
Oxazines/metabolism | 4 | 18.0 |
Fluvoxamine/*pharmacology | 5 | 20.0 |
Serotonin Antagonists/*pharmacokinetics | 2 | 50.0 |
Iron/metabolism | 2 | 1.0 |
Estrone/*metabolism | 4 | 66.0 |
P-Glycoprotein/*biosynthesis/genetics/metabolism | 2 | 100.0 |
Isoenzymes/*antagonists & inhibitors | 5 | 15.0 |
Enzyme Inhibitors/blood/*pharmacokinetics | 2 | 100.0 |
Chick Embryo | 2 | 0.0 |
Fluorescent Dyes | 5 | 1.0 |
Phenytoin/*pharmacology | 3 | 33.0 |
Liver Neoplasms/enzymology/pathology | 2 | 28.0 |
RNA, Messenger/isolation & purification | 2 | 2.0 |
Mixed Function Oxygenases/biosynthesis/*drug effects | 2 | 100.0 |
Calcium Channel Blockers/*pharmacokinetics | 4 | 66.0 |
Enzyme Inhibitors/*pharmacokinetics | 4 | 36.0 |
Indinavir/*pharmacokinetics | 2 | 100.0 |
Intestinal Absorption/*drug effects | 2 | 12.0 |
Microsomes, Liver/*drug effects/*enzymology | 2 | 40.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 5 | 29.0 |
Lung/*metabolism | 2 | 2.0 |
Mice, Inbred DBA | 2 | 0.0 |
Microsomes/*metabolism | 3 | 7.0 |
Steroid Hydroxylases/genetics/metabolism | 4 | 36.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/metabolism | 2 | 40.0 |
Disulfiram/*pharmacology | 2 | 28.0 |
Itraconazole/*pharmacology | 10 | 66.0 |
Quinidine/metabolism/*pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/metabolism | 4 | 66.0 |
Theophylline/analogs & derivatives/pharmacology | 7 | 31.0 |
Cytochrome P-450 CYP1A2/genetics/*metabolism | 3 | 12.0 |
Caffeine/*pharmacokinetics | 4 | 23.0 |
*Pharmacology | 2 | 50.0 |
Anti-Anxiety Agents/*pharmacokinetics/*pharmacology | 2 | 100.0 |
Benzodiazepines | 4 | 19.0 |
*Phenylpropanolamine | 3 | 100.0 |
HIV Protease Inhibitors/*metabolism/pharmacokinetics | 3 | 100.0 |
Saquinavir/*metabolism/pharmacokinetics | 2 | 100.0 |
Antimalarials/*metabolism | 6 | 75.0 |
Orphenadrine/pharmacology | 2 | 50.0 |
Sesquiterpenes/*metabolism | 4 | 100.0 |
Quinidine/*analogs & derivatives/blood | 3 | 100.0 |
Serotonin Uptake Inhibitors/pharmacology | 2 | 16.0 |
Biosensing Techniques/*methods | 2 | 18.0 |
Point Mutation | 2 | 0.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
*DNA Repair | 2 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Citalopram/chemistry/*metabolism | 2 | 100.0 |
Methylation/drug effects | 4 | 28.0 |
Acetonitriles | 2 | 50.0 |
Cytochrome P-450 Enzyme System/analysis/genetics/*metabolism | 2 | 100.0 |
Dimethylformamide | 2 | 100.0 |
Flunitrazepam/*metabolism | 3 | 60.0 |
DNA, Complementary/*biosynthesis | 5 | 41.0 |
*Ginsenosides | 2 | 22.0 |
Panax/*chemistry | 2 | 18.0 |
Saponins/*pharmacology | 2 | 20.0 |
DNA Footprinting | 2 | 0.0 |
Mifepristone/pharmacology | 5 | 6.0 |
Isoenzymes/drug effects/metabolism | 3 | 20.0 |
Midazolam/*metabolism | 5 | 71.0 |
B-Lymphocytes | 2 | 1.0 |
Baculoviridae | 2 | 3.0 |
Phthalazines/*metabolism | 2 | 100.0 |
Culture Techniques | 5 | 1.0 |
Fentanyl/*metabolism | 2 | 100.0 |
Antimalarials/administration & dosage/blood/*pharmacokinetics | 2 | 66.0 |
Chlorzoxazone/*pharmacokinetics | 2 | 33.0 |
Quinones/*metabolism | 2 | 50.0 |
Multivariate Analysis | 3 | 0.0 |
Sex Distribution | 2 | 0.0 |
Cross Reactions | 3 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*immunology | 2 | 66.0 |
Glucocorticoids/*pharmacology | 4 | 2.0 |
Glucuronosyltransferase/genetics | 3 | 18.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Anti-HIV Agents/*metabolism | 3 | 33.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/*metabolism | 4 | 80.0 |
Pyrans/*metabolism | 2 | 100.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 2 | 2.0 |
*Genetic Vectors | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Microsomes/drug effects/metabolism | 5 | 26.0 |
Pyridines/chemistry/metabolism | 2 | 100.0 |
Anti-Ulcer Agents/*metabolism | 3 | 60.0 |
Omeprazole/analogs & derivatives | 4 | 26.0 |
Proton Pumps/*antagonists & inhibitors | 2 | 10.0 |
Life Style | 2 | 1.0 |
Cytochrome P-450 Enzyme System/*analysis/genetics | 4 | 50.0 |
Mixed Function Oxygenases/*analysis/genetics | 3 | 60.0 |
Hypnotics and Sedatives/*metabolism | 4 | 57.0 |
Piperazines/*metabolism | 2 | 40.0 |
Escherichia coli/*enzymology | 2 | 12.0 |
Anesthetics, Intravenous/metabolism | 2 | 100.0 |
Escherichia coli/metabolism | 5 | 1.0 |
Propofol/*pharmacology | 2 | 25.0 |
Miconazole/pharmacology | 3 | 50.0 |
Recombinant Proteins/pharmacology | 6 | 0.0 |
Vasodilator Agents/pharmacology | 2 | 3.0 |
Antimalarials/blood/*pharmacokinetics/urine | 2 | 100.0 |
Databases | 2 | 2.0 |
Lung/*enzymology | 3 | 4.0 |
Cytochrome P-450 CYP2D6/chemistry | 2 | 100.0 |
Postoperative Period | 2 | 0.0 |
Antidepressive Agents/*pharmacokinetics | 3 | 100.0 |
Anticoagulants/*metabolism | 2 | 6.0 |
Drug Interactions/genetics | 2 | 50.0 |
Warfarin/*metabolism | 2 | 40.0 |
Hydrocortisone/blood | 2 | 0.0 |
Metabolic Clearance Rate/drug effects | 4 | 25.0 |
*Cryopreservation | 4 | 6.0 |
Glucuronosyltransferase/*biosynthesis | 2 | 20.0 |
*Organ Preservation | 2 | 16.0 |
Cell Survival/drug effects/physiology | 3 | 3.0 |
Formazans/metabolism | 2 | 40.0 |
Tetrazolium Salts/metabolism | 2 | 12.0 |
Antifungal Agents/administration & dosage/*pharmacology | 5 | 83.0 |
Receptors, Cytoplasmic and Nuclear/genetics/*metabolism | 3 | 6.0 |
Receptors, Steroid/genetics/*metabolism | 3 | 21.0 |
Cytochrome P-450 Enzyme System/drug effects/metabolism | 2 | 28.0 |
DNA Probes | 2 | 0.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
Frozen Sections | 2 | 2.0 |
Intestine, Small/cytology/*enzymology | 2 | 50.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics | 3 | 60.0 |
Colon/metabolism | 2 | 1.0 |
Intestine, Small/metabolism | 3 | 5.0 |
Antipsychotic Agents/pharmacokinetics/*pharmacology | 2 | 100.0 |
Erythromycin/pharmacokinetics/*pharmacology | 2 | 66.0 |
DNA/*analysis | 2 | 0.0 |
Clomipramine/*metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/drug effects | 5 | 50.0 |
Pentobarbital/pharmacology | 2 | 28.0 |
Pyridines/pharmacology | 2 | 0.0 |
Thiazoles/pharmacology | 2 | 1.0 |
Gene Library | 2 | 0.0 |
*Models, Chemical | 3 | 14.0 |
*European Continental Ancestry Group | 2 | 2.0 |
Catechols/*metabolism | 3 | 75.0 |
DNA Probes/genetics | 2 | 1.0 |
Gene Expression Regulation, Enzymologic/*genetics | 2 | 3.0 |
Mutation/genetics | 3 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
*Microsatellite Repeats | 2 | 0.0 |
Circadian Rhythm | 2 | 0.0 |
Terfenadine/*pharmacology | 2 | 40.0 |
Schizophrenic Psychology | 2 | 5.0 |
Alkaline Phosphatase/genetics | 2 | 8.0 |
Hormone Antagonists/pharmacology | 2 | 3.0 |
Isoniazid/pharmacology | 2 | 22.0 |
Steroid Hydroxylases/immunology/metabolism | 2 | 66.0 |
Isoenzymes/antagonists & inhibitors/immunology/metabolism | 2 | 66.0 |
Mixed Function Oxygenases/biosynthesis/genetics/*metabolism | 2 | 66.0 |
Testosterone/*metabolism/pharmacology | 2 | 100.0 |
Homozygote | 5 | 0.0 |
Nifedipine/blood/*pharmacokinetics | 2 | 50.0 |
Amines/*metabolism | 2 | 11.0 |
Heterocyclic Compounds/*metabolism | 3 | 30.0 |
Smoking/adverse effects | 2 | 0.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
Enzyme Inhibitors/adverse effects/*pharmacology | 2 | 66.0 |
Anesthetics, Local/*pharmacokinetics | 2 | 100.0 |
Placebos | 2 | 0.0 |
DNA, Complementary/*genetics | 3 | 1.0 |
Omeprazole/*metabolism | 4 | 66.0 |
Absorption | 6 | 4.0 |
Psoralens/*pharmacology | 3 | 42.0 |
Anti-Bacterial Agents/*pharmacology | 13 | 10.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/chemistry | 3 | 75.0 |
Diterpenes/pharmacology | 3 | 11.0 |
Goats | 2 | 2.0 |
Anti-Infective Agents/pharmacology | 2 | 11.0 |
Pregnenolone Carbonitrile/pharmacology | 2 | 25.0 |
Troleandomycin/*pharmacology | 3 | 50.0 |
Midazolam/blood/*pharmacokinetics | 2 | 33.0 |
Mucous Membrane/enzymology | 2 | 18.0 |
Cytochrome P-450 Enzyme System/chemistry/metabolism | 2 | 66.0 |
DNA, Complementary/genetics/metabolism | 2 | 4.0 |
Isoxazoles/*metabolism | 2 | 66.0 |
Pyrimidines/*metabolism | 2 | 28.0 |
Promoter Regions (Genetics)/*drug effects/physiology | 2 | 40.0 |
Felodipine/pharmacokinetics | 3 | 100.0 |
Food-Drug Interactions/*physiology | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/drug effects | 2 | 100.0 |
Intestines/drug effects/metabolism | 2 | 40.0 |
Antibody Specificity | 7 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
Autoradiography | 3 | 0.0 |
Imidazoles/*pharmacokinetics | 2 | 14.0 |
Kidney Diseases/metabolism | 3 | 11.0 |
Liver Diseases/metabolism | 3 | 17.0 |
Pyridines/*metabolism | 2 | 20.0 |
Trimethadione/*metabolism | 3 | 75.0 |
Anti-HIV Agents/*therapeutic use | 2 | 0.0 |
HIV Infections/complications/drug therapy | 2 | 20.0 |
*International Normalized Ratio | 2 | 40.0 |
Mixed Function Oxygenases/*drug effects | 2 | 66.0 |
Central Nervous System Stimulants/*pharmacokinetics | 2 | 22.0 |
Steroid Hydroxylases/antagonists & inhibitors/genetics/*metabolism | 2 | 50.0 |
Mixed Function Oxygenases/*biosynthesis/metabolism | 2 | 100.0 |
Biological Markers/urine | 3 | 4.0 |
Fetus/*metabolism | 2 | 2.0 |
Xenobiotics/metabolism | 4 | 9.0 |
Etoposide/pharmacology | 2 | 1.0 |
Tamoxifen/pharmacology | 2 | 2.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*blood | 2 | 100.0 |
DNA Primers/genetics | 3 | 0.0 |
Multigene Family/*genetics | 2 | 1.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics/therapeutic use | 2 | 50.0 |
Cyclosporine/pharmacokinetics | 4 | 80.0 |
Intestinal Absorption/physiology | 2 | 14.0 |
Saquinavir/pharmacokinetics | 2 | 100.0 |
Cholestenone 5 alpha-Reductase | 3 | 11.0 |
Free Radical Scavengers/pharmacology | 2 | 3.0 |
Oxidoreductases/*antagonists & inhibitors | 3 | 27.0 |
Pregnatrienes/*pharmacokinetics | 3 | 75.0 |
Tamoxifen/*metabolism | 3 | 33.0 |
ATP-Binding Cassette Transporters/*metabolism | 2 | 2.0 |
Organ Specificity/physiology | 2 | 13.0 |
Continental Population Groups | 2 | 1.0 |
Karyotyping | 2 | 0.0 |
Neoplasms, Second Primary/chemically induced/*genetics | 2 | 33.0 |
Itraconazole/administration & dosage/*pharmacology | 3 | 100.0 |
*Pharmacology, Clinical | 2 | 66.0 |
Clone Cells | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/*genetics/metabolism | 2 | 40.0 |
Mice, Inbred ICR | 2 | 0.0 |
Oxidoreductases, O-Demethylating/antagonists & inhibitors | 2 | 100.0 |
Disulfiram/*pharmacokinetics | 2 | 100.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Organ Culture Techniques | 2 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 2 | 2.0 |
Aroclor 1254/pharmacology | 2 | 66.0 |
Indoles/*pharmacology | 2 | 2.0 |
Etoposide/*metabolism | 2 | 100.0 |
Isoenzymes/physiology | 2 | 4.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Antibodies, Viral/immunology | 2 | 2.0 |
Biopsy | 2 | 0.0 |
Bone Neoplasms/pathology/virology | 2 | 33.0 |
Carcinoma, Squamous Cell/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cell Differentiation | 4 | 0.0 |
Cell Line, Tumor/metabolism/virology | 2 | 28.0 |
Cell Nucleus/virology | 2 | 15.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Cell Transformation, Viral/genetics | 2 | 8.0 |
Cervical Intraepithelial Neoplasia/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cervix Neoplasms/etiology/*genetics/pathology/virology | 2 | 33.0 |
Cervix Uteri/pathology/*virology | 2 | 28.0 |
Epithelial Cells/ultrastructure/virology | 2 | 33.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Oncogene Proteins, Viral/biosynthesis/genetics/immunology/*physiology | 2 | 33.0 |
Osteosarcoma/pathology/virology | 2 | 33.0 |
Papillomavirus Infections/*genetics | 2 | 25.0 |
Papillomavirus, Human/genetics/*pathogenicity | 2 | 25.0 |
Retinoblastoma Protein/*metabolism | 2 | 1.0 |
Tumor Virus Infections/*genetics | 2 | 18.0 |
Heart Rate/drug effects | 5 | 2.0 |
Heptanoic Acids/*pharmacology | 2 | 9.0 |
Pyrroles/*pharmacology | 2 | 4.0 |
Antidepressive Agents/adverse effects/*pharmacokinetics | 2 | 100.0 |
Mixed Function Oxygenases/drug effects | 2 | 50.0 |
NADH, NADPH Oxidoreductases/genetics/*metabolism | 3 | 50.0 |
NADPH-Ferrihemoprotein Reductase | 4 | 30.0 |
Isoenzymes/biosynthesis/genetics/*metabolism | 2 | 22.0 |
Methoxychlor/*metabolism | 3 | 60.0 |
Breast Neoplasms/drug therapy | 2 | 6.0 |
Endometriosis/drug therapy | 2 | 50.0 |
Progestins/*antagonists & inhibitors | 2 | 28.0 |
Epitopes | 2 | 0.0 |
Sparteine/pharmacology | 2 | 100.0 |
Terpenes/*pharmacology | 3 | 15.0 |
Alprazolam/*pharmacokinetics | 4 | 66.0 |
Cisapride | 2 | 40.0 |
Triazolam/pharmacology | 2 | 100.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 7 | 46.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*physiology | 5 | 83.0 |
Anti-HIV Agents/*pharmacokinetics | 3 | 60.0 |
Cytochrome P-450 Enzyme System/analysis/*metabolism | 2 | 28.0 |
Isoenzymes/analysis/*metabolism | 2 | 25.0 |
Xenobiotics/pharmacokinetics | 2 | 28.0 |
Epoxide Hydrolases/metabolism | 3 | 18.0 |
Propylene Glycols/pharmacology | 2 | 40.0 |
Dehydroepiandrosterone/metabolism | 2 | 11.0 |
*Biological Clocks | 2 | 8.0 |
*Circadian Rhythm | 2 | 0.0 |
Flavoproteins/genetics | 2 | 11.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Stochastic Processes | 2 | 5.0 |
Drug Administration Routes | 2 | 10.0 |
Blood Loss, Surgical/statistics & numerical data | 12 | 48.0 |
Blood Transfusion/utilization | 12 | 50.0 |
Cost-Benefit Analysis | 12 | 10.0 |
Hospital Costs/statistics & numerical data | 12 | 48.0 |
Length of Stay/statistics & numerical data | 12 | 35.0 |
Osteoarthritis, Knee/epidemiology/*surgery | 12 | 52.0 |
*Outcome Assessment (Health Care) | 12 | 27.0 |
Perioperative Care | 12 | 48.0 |
Postoperative Complications/epidemiology | 12 | 24.0 |
Turkey/epidemiology | 12 | 16.0 |
Antipsychotic Agents/pharmacology | 2 | 15.0 |
*Ginkgo biloba | 2 | 66.0 |
Enzyme Activation/drug effects/physiology | 2 | 3.0 |
Lovastatin/*blood | 2 | 100.0 |
Cytokines/pharmacology | 2 | 0.0 |
Glutathione Transferase/*metabolism | 2 | 6.0 |
Placenta/*enzymology | 2 | 2.0 |
Chromatography, Liquid/methods | 3 | 13.0 |
Isoenzymes/*physiology | 5 | 15.0 |
Saquinavir/*pharmacokinetics | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*analysis/antagonists & inhibitors | 3 | 75.0 |
Mixed Function Oxygenases/*analysis | 3 | 27.0 |
Naproxen/metabolism | 2 | 40.0 |
Imidazoles/blood/*pharmacokinetics | 2 | 100.0 |
Tissue Donors | 2 | 0.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Receptors, Cytoplasmic and Nuclear/*genetics | 3 | 4.0 |
Receptors, Steroid/*genetics | 3 | 13.0 |
Cyclosporine/metabolism | 2 | 22.0 |
Aflatoxin B1/pharmacokinetics/toxicity | 2 | 100.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Antineoplastic Agents, Hormonal/*metabolism | 2 | 50.0 |
Endometrium/*enzymology | 2 | 18.0 |
Estrogen Antagonists/*metabolism | 2 | 33.0 |
RNA, Messenger | 2 | 0.0 |
Swine, Miniature/*metabolism | 2 | 100.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Liver/embryology/*enzymology | 2 | 18.0 |
Anti-Inflammatory Agents, Non-Steroidal/*metabolism | 3 | 33.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/metabolism | 3 | 23.0 |
Fetus | 3 | 0.0 |
*Gene Expression Regulation, Developmental | 3 | 0.0 |
Down-Regulation/drug effects | 4 | 1.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Antibiotics, Antitubercular/metabolism | 2 | 100.0 |
Indinavir/*pharmacology | 2 | 33.0 |
Ritonavir/*pharmacology | 3 | 37.0 |
Saquinavir/*pharmacology | 3 | 60.0 |
Oxygen Isotopes | 2 | 28.0 |
Antineoplastic Agents/blood/*pharmacokinetics | 2 | 100.0 |
Glucuronosyltransferase/metabolism | 5 | 18.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis/genetics | 4 | 25.0 |
Isoenzymes/drug effects | 2 | 66.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics/*metabolism | 3 | 37.0 |
Macrophages, Alveolar/*enzymology | 2 | 22.0 |
Guinea Pigs | 8 | 0.0 |
Dexamethasone/*metabolism | 2 | 50.0 |
Estradiol Congeners/*pharmacology | 2 | 22.0 |
Isoenzymes/biosynthesis/genetics | 5 | 10.0 |
Hydrocortisone/diagnostic use | 2 | 100.0 |
Steroid Hydroxylases/*physiology | 3 | 50.0 |
Cytochrome P-450 Enzyme System/analysis/*physiology | 3 | 75.0 |
Mixed Function Oxygenases/analysis/*physiology | 2 | 100.0 |
Depressive Disorder/drug therapy/metabolism | 2 | 50.0 |
Protein Synthesis Inhibitors/administration & dosage/*pharmacology | 2 | 66.0 |
Cyclosporine/administration & dosage/*pharmacokinetics | 3 | 30.0 |
Immunosuppressive Agents/administration & dosage/*pharmacokinetics | 3 | 37.0 |
Leukemia, Lymphocytic, Acute, L1/drug therapy | 2 | 50.0 |
Indoles/pharmacology | 2 | 0.0 |
Hormone Antagonists/*metabolism | 2 | 100.0 |
Norpregnenes/pharmacology | 4 | 44.0 |
Valproic Acid/pharmacokinetics | 2 | 66.0 |
Recombinant Proteins/*biosynthesis | 2 | 5.0 |
Glucuronosyltransferase/*biosynthesis/genetics | 2 | 22.0 |
1-Naphthylamine/analogs & derivatives/pharmacokinetics | 2 | 100.0 |
Fluvoxamine/pharmacokinetics | 2 | 100.0 |
Paroxetine/pharmacokinetics | 2 | 66.0 |
Sertraline | 3 | 30.0 |
Liver/cytology/drug effects/*enzymology | 2 | 25.0 |
Progestins/antagonists & inhibitors | 2 | 33.0 |
Anti-Ulcer Agents/*pharmacology | 2 | 9.0 |
Anticonvulsants/pharmacokinetics | 2 | 50.0 |
Omeprazole/*pharmacology | 2 | 8.0 |
Calcium Channel Blockers/*metabolism | 2 | 50.0 |
Introns/genetics | 2 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
CCAAT-Enhancer-Binding Protein-alpha/*physiology | 2 | 50.0 |
DNA-Binding Proteins/*physiology | 3 | 0.0 |
Nuclear Proteins/*physiology | 3 | 2.0 |
Transcription Factors/*physiology | 3 | 0.0 |
Culture Media, Serum-Free | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Isoenzymes/biosynthesis | 4 | 8.0 |
RNA/analysis | 2 | 0.0 |
Carcinogens/*metabolism | 6 | 7.0 |
Cell Separation | 2 | 0.0 |
Intestinal Mucosa/cytology/*metabolism | 2 | 9.0 |
Oxidoreductases, N-Demethylating/*biosynthesis/genetics | 2 | 20.0 |
Calcium Channel Blockers/blood/*pharmacokinetics | 2 | 66.0 |
Smoking | 2 | 0.0 |
Catalase/metabolism | 2 | 3.0 |
Isoenzymes/immunology/*metabolism | 3 | 50.0 |
Aflatoxin B1/*metabolism | 4 | 50.0 |
DNA Adducts/metabolism | 2 | 5.0 |
*Herb-Drug Interactions | 2 | 66.0 |
Phytotherapy | 2 | 7.0 |
Callithrix | 2 | 2.0 |
Nifedipine/*metabolism | 2 | 50.0 |
Anti-Anxiety Agents/*pharmacology | 2 | 14.0 |
Neutrophils/drug effects | 2 | 3.0 |
Antidepressive Agents/pharmacology | 2 | 33.0 |
Carbon Dioxide/metabolism | 2 | 6.0 |
Liver/*enzymology/metabolism | 3 | 18.0 |
Anticonvulsants/adverse effects/*pharmacokinetics | 2 | 100.0 |
Umbelliferones/urine | 3 | 42.0 |
Antidepressive Agents, Second-Generation/*pharmacokinetics | 2 | 100.0 |
Citalopram/pharmacokinetics | 2 | 100.0 |
Cell Division/drug effects | 3 | 0.0 |
Antipsychotic Agents/chemistry/*metabolism | 2 | 100.0 |
Phenothiazines/chemistry/*metabolism | 2 | 100.0 |
Catalysis/drug effects | 2 | 10.0 |
*Genotype | 2 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
Cytochrome P-450 CYP2E1 | 20 | 19.0 |
Multigene Family | 3 | 0.0 |
Enzyme Inhibitors/*blood | 2 | 40.0 |
*Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 10.0 |
Cytochrome P-450 Enzyme System/*drug effects/*metabolism | 2 | 66.0 |
Immunosuppressive Agents/pharmacokinetics/therapeutic use | 2 | 50.0 |
Tacrolimus/pharmacokinetics/therapeutic use | 2 | 100.0 |
Chronic Disease | 6 | 0.0 |
Cytochrome P-450 CYP1A2 | 10 | 11.0 |
Membrane Potentials | 2 | 0.0 |
Hemodynamic Processes/drug effects | 3 | 1.0 |
Erythromycin/*pharmacokinetics | 2 | 33.0 |
Cyclosporine/*metabolism | 2 | 28.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Antimalarials/pharmacology | 2 | 11.0 |
Mixed Function Oxygenases/*analysis/antagonists & inhibitors | 2 | 100.0 |
Lac Operon | 2 | 1.0 |
Fluorescence | 2 | 0.0 |
Verapamil/*metabolism | 2 | 66.0 |
Mutagens/*metabolism | 2 | 5.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Tetrachlorodibenzodioxin/pharmacology | 2 | 2.0 |
Indoles/*metabolism | 2 | 18.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/metabolism | 2 | 5.0 |
Aflatoxin B1/toxicity | 2 | 22.0 |
Cell Survival | 2 | 0.0 |
DNA, Complementary/biosynthesis/genetics | 7 | 16.0 |
Theophylline/*metabolism | 2 | 40.0 |
Colon/enzymology | 2 | 7.0 |
Subcellular Fractions | 2 | 1.0 |
Intestine, Small/enzymology | 2 | 12.0 |
Quinolines/metabolism | 2 | 18.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/genetics | 2 | 33.0 |
*Breath Tests | 4 | 33.0 |
Prodrugs/*metabolism | 2 | 40.0 |
Aryl Hydrocarbon Hydroxylases/*biosynthesis | 4 | 25.0 |
Receptors, Cytoplasmic and Nuclear/genetics | 3 | 7.0 |
Receptors, Steroid/genetics | 2 | 25.0 |
Neoplasm Transplantation | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Erythromycin/*metabolism | 2 | 40.0 |
Oxidoreductases/analysis/*physiology | 2 | 100.0 |
Ethylene Glycols/metabolism | 2 | 40.0 |
Styrene | 2 | 28.0 |
Models, Statistical | 2 | 1.0 |
Heart Transplantation/*physiology | 2 | 9.0 |
Kidney Transplantation/*physiology | 2 | 4.0 |
Antiemetics/*pharmacology | 2 | 40.0 |
Morpholines/*pharmacology | 2 | 11.0 |
Receptors, Neurokinin-1/antagonists & inhibitors | 2 | 100.0 |
Immunosuppressive Agents/*administration & dosage | 2 | 6.0 |
Drugs, Chinese Herbal/*pharmacology | 2 | 4.0 |
*Phenotype | 3 | 1.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis | 2 | 18.0 |
Cercopithecus aethiops | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 6 | 1.0 |
Glucuronides/metabolism | 2 | 4.0 |
Fluorometry | 2 | 2.0 |
Carcinogens/*metabolism/toxicity | 2 | 12.0 |
Family | 2 | 0.0 |
*Genetics, Population | 2 | 0.0 |
Quinolines/*pharmacokinetics | 2 | 20.0 |
Platelet Aggregation Inhibitors/*pharmacology | 3 | 4.0 |
Ticlopidine/*analogs & derivatives/*pharmacology | 2 | 100.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Saccharomyces cerevisiae/*enzymology | 2 | 9.0 |
Enzyme Stability/genetics | 2 | 7.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Organ Size | 2 | 1.0 |
DNA/biosynthesis/genetics | 2 | 9.0 |
Cytochrome P-450 Enzyme System/*pharmacology | 2 | 100.0 |
DNA/*metabolism | 3 | 0.0 |
Prostatic Neoplasms/*genetics | 3 | 1.0 |
Pyrimidines/administration & dosage/adverse effects/*pharmacokinetics | 5 | 100.0 |
Triazoles/administration & dosage/adverse effects/*pharmacokinetics | 5 | 100.0 |
HT29 Cells | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Receptors, Steroid/*genetics/metabolism | 2 | 25.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis/genetics | 2 | 28.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Anticonvulsants/metabolism | 2 | 33.0 |
Calcitriol/pharmacology | 3 | 2.0 |
Gene Expression Regulation, Enzymologic/drug effects/physiology | 2 | 6.0 |
Pharmacogenetics/*methods | 2 | 11.0 |
Disease Models, Animal | 4 | 0.0 |
Indinavir/*blood/*pharmacokinetics | 2 | 100.0 |
Mutagens/toxicity | 3 | 8.0 |
Arthritis, Rheumatoid/*complications/radiography | 2 | 10.0 |
Atlanto-Axial Joint/radiography | 2 | 10.0 |
*Cervical Vertebrae/radiography | 2 | 9.0 |
Dislocations/etiology/radiography | 2 | 10.0 |
Neck Pain/etiology | 2 | 10.0 |
Spinal Diseases/*etiology/radiography | 2 | 10.0 |
Body Mass Index | 2 | 0.0 |
Energy Intake | 2 | 1.0 |
Exercise/*physiology | 2 | 0.0 |
*Leisure Activities | 2 | 6.0 |
Motor Activity/physiology | 2 | 2.0 |
Obesity/epidemiology/*etiology | 2 | 6.0 |
Self Disclosure | 2 | 6.0 |
Television | 2 | 5.0 |
Influenza Vaccines/administration & dosage | 2 | 22.0 |
Interviews | 3 | 7.0 |
Italy | 2 | 0.0 |
Pneumococcal Vaccines/administration & dosage | 2 | 28.0 |
Sampling Studies | 2 | 1.0 |
Tetanus Toxoid/administration & dosage | 2 | 20.0 |
Vaccination/*trends | 2 | 28.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Liver/embryology/enzymology | 2 | 11.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/*metabolism | 4 | 23.0 |
Genes, MDR | 2 | 6.0 |
Glucuronosyltransferase/genetics/metabolism | 2 | 15.0 |
P-Glycoprotein/genetics | 2 | 6.0 |
Cyclosporine/*blood | 2 | 33.0 |
Immunosuppressive Agents/*blood | 2 | 22.0 |
Ion Channel Gating | 2 | 2.0 |
Bicuspid/radiography | 2 | 100.0 |
Carbon/diagnostic use | 2 | 100.0 |
*Contrast Media | 2 | 7.0 |
Dental Pulp Cavity/*radiography | 2 | 100.0 |
Dyes/diagnostic use | 2 | 2.0 |
False Positive Reactions | 2 | 0.0 |
Iohexol/*analogs & derivatives/diagnostic use | 2 | 100.0 |
Observer Variation | 2 | 1.0 |
Pulpectomy | 2 | 100.0 |
Root Canal Preparation | 2 | 100.0 |
*Root Canal Therapy | 2 | 100.0 |
Tooth Apex/radiography | 2 | 100.0 |
Tooth Root/radiography | 2 | 66.0 |
Computational Biology | 2 | 1.0 |
Disease-Free Survival | 2 | 0.0 |
RNA, Messenger/genetics/*metabolism | 2 | 1.0 |
Gene Frequency/genetics | 4 | 0.0 |
Living Donors | 2 | 4.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 3 | 12.0 |
Molecular Probes | 2 | 3.0 |
Enzymes, Immobilized | 2 | 50.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*biosynthesis | 2 | 33.0 |
Hepatocytes/*drug effects/metabolism | 2 | 18.0 |
Enzyme Inhibitors/administration & dosage/*pharmacokinetics | 2 | 66.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*metabolism | 4 | 50.0 |
Recombinant Proteins/antagonists & inhibitors/*metabolism | 2 | 66.0 |
Heterozygote | 2 | 0.0 |
*Pyrimidines | 3 | 60.0 |
*Sulfonamides | 3 | 5.0 |
Hypoglycemic Agents/pharmacology | 2 | 6.0 |
Receptors, Endothelin/*antagonists & inhibitors | 2 | 15.0 |
Sulfonamides/*pharmacokinetics | 2 | 50.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
Spectrum Analysis, Mass/methods | 2 | 5.0 |
Tamoxifen/*analogs & derivatives/*metabolism | 2 | 66.0 |
HIV Protease Inhibitors/*pharmacokinetics/*pharmacology | 2 | 100.0 |
